High-throughput molecular tests for routine surveillance of malaria potentially missed by rapid diagnostic tests by Guirou, Etienne dit Anagalou
High-throughput molecular tests for                     
routine surveillance of malaria potentially missed by 
rapid diagnostic tests 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
Etienne dit Anagalou Guirou 
 
Basel, 2020 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
https://edoc.unibas.ch 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. 
Claudia Daubenberger, Prof. Dr. Marcel Tanner und Prof. Dr. Steffen Borrmann. 
 
Basel, den 18. Februar 2020 
 
Prof. Dr. Martin Spiess 
Dekan 
 
 i 
 
Table of Contents 
Summary .................................................................................................................................. iii 
Acknowledgments.................................................................................................................... vii 
List of Abbreviations ............................................................................................................. viii 
Introduction ................................................................................................................................ 1 
1. Current situation of Malaria ............................................................................................... 1 
2. Plasmodium spp. life cycle and pathogenesis .................................................................... 2 
2.1 Life cycle ..................................................................................................................... 2 
2.2 Pathogenesis of P. falciparum infections..................................................................... 5 
3. Diagnosis ............................................................................................................................ 7 
3.1 Microscopy .................................................................................................................. 7 
3.2 Rapid diagnostic test .................................................................................................... 8 
3.3 Polymerase chain reaction ........................................................................................... 8 
3.4 Diagnosis of malaria in pregnancy .............................................................................. 9 
4. Malaria prevention and surveillance .................................................................................. 9 
4.1 Prevention .................................................................................................................... 9 
4.2 Surveillance................................................................................................................ 10 
4.3 Vaccines ..................................................................................................................... 11 
5. Aims of the thesis ............................................................................................................. 14 
Tools and techniques for high-throughput molecular malaria surveillance ............................. 15 
A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene deletions in multiple 
strain infections of Plasmodium falciparum ............................................................................ 62 
Malaria prevalence in pregnant women established by molecular tests after introduction of 
intermittent preventive treatment on Bioko Island, Equatorial Guinea ................................... 73 
HIV infection negatively impacts the vaccine efficacy of whole irradiation attenuated 
sporozoite based malaria vaccines when evaluated by homologous controlled human malaria 
infections .................................................................................................................................. 97 
 ii 
 
General discussion ................................................................................................................. 113 
6.1 The importance of implementing molecular tools in malaria surveillance programs .. 114 
6.2 Why extract nucleic acids from used malaria rapid diagnostic tests? .......................... 114 
6.3 Monitoring Plasmodium falciparum strains lacking histidine-rich protein 2 and 3 genes
 ............................................................................................................................................ 118 
6.4 Molecular surveillance of malaria in pregnant women on Bioko Island ................ 120 
6.5 Following Plasmodium falciparum parasitaemia in HIV positive volunteers 
undergoing CHMI .............................................................................................................. 122 
Conclusion and Outlook ........................................................................................................ 123 
References .............................................................................................................................. 126 
Curriculum Vitae ................................................................................................................... 143 
 
 iii 
 
Summary 
 
Malaria remains one of the most common infectious diseases in the world and still a public 
health problem particularly in sub-Saharan Africa despite the remarkable progress made during 
the past decades in cutting the number of cases by around 50 %. Improvement in diagnosis and 
the introduction of artemisinin-based therapies have contributed substantially to this 
development. 
Currently available diagnosis tools for the identification of P. falciparum include the gold 
standard TBS microscopy and RDT. Despite many advantages, currently deployed RDTs have 
severe limitations in detecting low-density parasitemia. P. falciparum isolates lacking the hrp2 
and hrp3 genes escape RDT detection posing a serious threat to the currently deployed test-
treat-track approach for malaria recommended by WHO. False positive RDTs based on 
circulating HRP2 protein after successful asexual blood stage clearance following treatment 
have been described. RDTs with high sensitivity and specificity for monitoring non-falciparum 
species are missing. Therefore, improved diagnostic tools for rapid surveillance of malaria are 
essential for approaching the final aim of malaria elimination. 
The main goal of this PhD thesis is to develop, validate and implement novel tools and 
techniques for high-throughput molecular detection that will support a comprehensive 
surveillance of malaria by  (i) measuring prevalence of P. falciparum parasites potentially 
escaping detection by RDTs, (ii) monitoring of kelch13 gene mutations conferring artemisinin 
resistance, (iii) monitoring impact of preventive treatment programs in pregnant women, (iv) 
understand the interaction of co-infections like HIV on P. falciparum, (v) assess the 
epidemiology of Plasmodium spp. co-infections with P. falciparum.  
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Manuscript 1: Molecular malaria surveillance using a novel protocol for extraction and 
analysis of nucleic acids retained on used rapid diagnostic tests 
This manuscript describes the use of malaria rapid diagnostic tests (RDTs) strips as a source 
for total nucleic acids at large-scale in order to screen for SNPs in an artimisinin-associated 
drug resistance marker among thousands of healthy, malaria asymptomatic individuals. 
We compared four extraction protocols side by side and focused on developing the one with 
superior performance and taking into account the cost and ability to co-extract RNA.  
Next, we developed the ENAR (Extraction of Nucleic Acids from RDTs) approach for large-
scale molecular malaria surveillance using thousands of RDTs collected during the malaria 
indicator survey (MIS) 2018 on Bioko Island, Equatorial Guinea. We found several, known 
and new, nonsynonymous SNPs in the propeller region of the kelch 13 gene among isolates 
circulating on the Island. 
 
Manuscript 2: ELIMU-MDx: A Web-Based, Open-Source Platform for Storage, 
Management and Analysis of Diagnostic qPCR Data 
In order to manage properly the vast amount of qPCR data generated during Controlled Human 
Malaria Infections and other epidemiological studies, we developed a web-based and open-
source software for storage, management and analysis of diagnostic qPCR data.  
The ELIMU platform is being used in house for large-scale analysis and interpretation of 
diagnostic qPCR data. 
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Manuscript 3: A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene 
deletions in multiple strain infections of Plasmodium falciparum 
Here, we developed a qPCR-based assay suitable for high-throughput identification of pfhrp2 
and pfhrp3 gene deletions in P. falciparum isolates, in response to the emerging threat of P. 
falciparum strains lacking pfhrp2 and/or pfhrp3 genes and therefore not detected by PfHRP2-
based RDTs. The assay is particularly interesting because it allows to detect “masked” pfhrp2/3 
deletions in multiple strains P. falciparum co-infections. This feature of the assay allows to 
study the epidemiology of pfhrp2/3 deletions in malaria endemic regions where the prevalence 
of multiple strains P. falciparum infections is high. 
 
Manuscript 4: Malaria prevalence in pregnant women established by molecular tests 
after introduction of intermittent preventive treatment on Bioko Island, Equatorial 
Guinea 
Women living in malaria endemic regions particularly in first and second pregnancies have 
higher risk of malaria, with serious adverse effects for the woman and the child.  
We describe here the prevalence and molecular characteristics of Plasmodium infections in 
pregnant women covering the first, second and third trimester of pregnancy, by utilising the 
RDTs collected during the MIS 2018 on Bioko Island. We found that the prevalence of malaria 
infection in pregnant women was lower than in non-pregnant women on the Island, 
underscoring that implementation of preventive measures targeting this vulnerable population 
is effective. Although less pregnant women were infected with P. falciparum, they were more 
likely to suffer from anaemia. Using the MIS 2018, we were able to identify malaria-infected 
women in their first trimester who should be encouraged to come early to antenatal care 
facilities.   
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Manuscript 5: HIV infection negatively impacts the vaccine efficacy of whole irradiation 
attenuated sporozoite based malaria vaccines when evaluated by homologous controlled 
human malaria infections 
Malaria and HIV are co-endemic in many regions of Sub-Saharan Africa. Deployment of a 
malaria vaccine in the general population will require that the vaccine is safe and efficacious 
in all volunteers, irrespective of their HIV infection status. Here, we have vaccinated a group 
of HIV positive and HIV negative volunteers in Tanzania with irradiation attenuated purified 
Plasmodium falciparum sporozoites to compare the safety, immunogenicity and protective 
efficacy against homologous controlled human malaria infection. This is the first time that HIV 
positive volunteers have undergone controlled human malaria infection providing the 
opportunity to understand under highly controlled conditions the interaction between HIV and 
malaria. This trial has been registered at ClinicalTrials.gov Identifier: NCT03420053. 
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Introduction 
1. Current situation of Malaria 
Malaria is one of the most common infectious diseases in the world and remains a public health 
problem particularly in sub-Saharan Africa despite the remarkable progress made during the 
past decades (1). Six species of Plasmodium infect humans: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae, Plasmodium knowlesi, Plasmodium ovale curtisi 
and Plasmodium ovale wallikeri (2). Worldwide, approximately 219 million cases of malaria 
and 435 000 related deaths occurred in 2017 and most of these cases and deaths were in children 
under the age of five years and pregnant women in Africa (3). P. falciparum is the most 
dangerous species causing the highest level of morbidity and mortality (1). P. falciparum-
infected erythrocytes adhere to the endothelium of capillaries, leading to obstruction of the 
microcirculation and local tissue anoxia in vital organs such as the brain (cerebral malaria), the 
kidneys (renal failure) or the intestines (bacteraemia) (4, 5). Another manifestation of severe 
malaria is severe anaemia in high transmission settings, which is usually the consequence of 
destruction of erythrocytes of all age during schizogony, insufficient erythropoiesis and 
accelerated splenic removal of unparasitised red blood cells (6, 7). Sub-Saharan Africa is the 
most malaria-affected continent because of the presence of highly efficient transmitting vectors 
Anopheles gambiae and Anopheles funestus and the predominance of P. falciparum (8, 9) 
(Figure 1).  
In addition to morbidity and mortality, the disease has a significant economic and social burden 
for endemic countries (10-12). Indeed, a comparison of income in malaria affected and non-
affected countries indicated more than a fivefold difference in Gross Domestic Product (10). 
Furthermore, the cognitive abilities and school performance are impaired in children following 
malaria infection (13, 14).  
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Approximately 125 million pregnant women are at risk of malaria each year with around 32 
million of them living in Africa (15). P. falciparum and P. vivax are most commonly implicated 
in the occurrence of adverse pregnancy outcomes (15), however, the effect in pregnancy of the 
other four species are largely unknown (16, 17).  
 
 
Figure 1. A map of malaria-endemic region (reproduced from Phillips MA et al., Malaria. 
Nature Reviews Disease Primers. 2017; 3:17050, with the publisher’s permission) 
 
2. Plasmodium spp. life cycle and pathogenesis 
2.1 Life cycle 
The Plasmodium parasite has a complex life cycle that alternates between the intermediate 
human host and the definitive host Anopheles mosquito (Figure 2). 
2.1.1 Parasite 
In 1880, Charles Louis Alphonse Laveran discovered the malaria parasite Plasmodium (18). 
Plasmodium belongs to the phylum Apicomplexa, the order Haemosporida, the family of 
Plasmodiidae, and to the genus Plasmodia. Apicomplexans are obligate intracellular parasites 
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with a complex life cycle involving both asexual sporozoite and merozoite stages and sexual 
gametocyte stage (19).  
2.1.2 Vector 
In 1897, Ronald Ross discovered that mosquitoes transmitted malaria. The female mosquitoes 
that transmit malaria belong to the phylum Arthropoda, the order Diptera, the family of 
Culicidae, and to the genus Anopheles. Among 25 anopheline species in the world, An. 
gambiae complex and An. funestus represent the primary vectors in Africa (8, 9). The most 
effective vectors are characterized by their long lifespan, adaptation to the environment, rapid 
reproduction and anthropophily (9). Two applicable measures for malaria vector control are 
insecticide-treated nets (ITNs) and indoor residual spraying (IRS) (20).  
2.1.3 Life cycle 
 
Figure 2. Overview of the Life cycle of Plasmodium spp. (reproduced from Phillips MA et 
al., Malaria. Nature Reviews Disease Primers. 2017; 3:17050, with the publisher’s permission) 
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Malaria parasite development requires the Anopheles mosquitoe and human host to complete 
the life cycle. The cycle starts when a feeding female Anopheles mosquito inoculates around 
1-100 motile sporozoites into the dermis of a human host (21). The fate of these sporozoites is 
not clearly known, but they can take 1–3 hr to exit the dermis. The sporozoites rapidly reach 
the liver within 30-60 minutes transported in the bloodstream, and traverse through Küpffer 
cells and several hepatocytes before finally infecting a suitable hepatocyte (22). In the 
hepatocyte, the sporozoites undergo many asexual replications and differentiate into 
trophozoites and subsequently schizonts. This hepatic phase of infection is asymptomatic and 
last 6-10 days (9, 23). A successful sporozoite releases 10000-40000 infectious merozoites into 
the bloodstream, where they invade circulating erythrocytes and initiate the clinically important 
intra-erythrocytic cycle lasting 24 to 72 hours depending on the Plasmodium species. In the 
case of P. vivax and P. ovale, some merozoites enter into a dormant stage or hypnozoite that 
can persist in the liver for weeks or years before re-entering the bloodstream, and cause disease 
relapse (24). Others merozoites differentiate into female and male gametocytes through a 
process not yet completely understood of sexual differentiation in 3-10 days (25). Gametocytes 
concentrate in skin capillaries and are ingested by the mosquito vector during a blood meal 
(25). In the gut of the mosquito, each male gametocyte produces eight microgametes after three 
rounds of mitosis; the female gametocyte matures into a macrogamete. At least one male and 
one female stage V gametocytes have to be ingested by a female Anopheles mosquito during a 
blood meal to continue the cycle. The gametocytes male and female fuse into a diploid zygote 
in the mosquito’s midgut. The zygote develops into a motile ookinete that penetrate the 
mosquito’s midgut epithelial cells to form an oocyst. Oocysts undergo cycles of replication and 
form sporozoites. It takes around 10-14 days from fertilization to sporozoites maturation (25). 
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Upon release, sporozoites migrate from the abdomen to the salivary glands of the mosquito, 
where they can infect a human host and thereby perpetuate the life cycle. 
 
2.2 Pathogenesis of P. falciparum infections 
The pre-erythrocytic stage in hepatocytes is clinically silent. The erythrocytic asexual stage 
induces all the clinical manifestations. Symptoms of malaria are unspecific such as fever, 
headache, fatigue, muscle and joint aches, chills, perspiration and vomiting (9). 
In young children and non-immune individuals, the clinical manifestation is more patent and 
can rapidly become life threatening. They are more susceptible to respiratory distress, cerebral 
malaria and severe anaemia. Factors that affect the severity of malaria infection include host 
immune status and the causative Plasmodium species (26, 27). 
The rupture of infected erythrocytes releases hemozoin and stimulate pro-inflammatory 
cytokines such as tumour necrosis factor (TNF) and interleukin-1 and leads to clinical 
symptoms (28-30). The pathogenesis of anaemia in P. falciparum malaria is multifactorial. In 
malaria naïve individuals and without comorbidities, red blood cell loss is an important 
mechanism of anaemia (6). On the contrary, the reduction of erythropoiesis is likely to play an 
important role in patients living in endemic areas and with chronic low-density P. falciparum 
infections (31).  
Cytoadherence plays an important role in the pathogenesis of severe malaria. During the intra-
erythrocytic maturation, the parasite exports several proteins (32) that are important for 
cytoadherence to endothelial cells and rosetting (4, 33). These proteins are encoded by 
members of large polymorphic multigene families such as the var, the subtelomeric variable 
open reading frame (stevor) or repetitive interspersed family (rif) families (34, 35). The most 
characterized of these proteins is the multigene family Plasmodium falciparum Erythrocyte 
Membrane Protein 1 (PfEMP1) (36). Other proteins that are exported to the surface of infected 
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red blood cells include the Ring-Infected Erythrocyte Surface Antigen (RESA) (37) and the 
knob-associated histidine-rich protein (KAHRP) (38).  
Sequestration constitutes an immune evasion strategy for the parasite by preventing splenic 
clearance of infected erythrocytes (23). It follows the adhesion of PfEMP1 to host cell surface 
receptors such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 
(VCAM-1) (39), chondroitin sulphate A (CSA), hyaluronic acid (HA), and CD36 (40). P. 
falciparum-infected red blood cells are also able to adhere to uninfected ones forming 
conglomerates or “rosettes”. Cytoadherence and rosetting result in the clogging of vascular 
structures of various organs such as the brain, intestine, kidney and lung (5, 41).Pregnant 
women, especially during their first and second pregnancies have an increased susceptibility to 
malaria compared to non-pregnant women and are also more attractive to mosquitoes (42). The 
vulnerability is more important among women who have not yet developed adequate 
pregnancy-specific immune responses against the subpopulation of parasites that sequester in 
the placenta (43). Different approaches have been used to investigate the immunity observed 
in pregnancy across many studies indicated a parity-dependent acquisition of antibody against 
placental parasites or CSA-binding laboratory isolates (44). Higher levels of antibodies in 
multigravidae compared with primigravidae have been reported from many countries (45-47). 
Although the vast majority of pregnant women infected are asymptomatic (48), malaria can 
result in low birth weight (LBW) and maternal anaemia (49), increasing maternal, neonatal and 
infant mortality (50). The contribution of malaria as a cause of preterm delivery and intrauterine 
growth retardation is remarkably high in malaria endemic areas of Africa (49, 51). 
Malaria infection during pregnancy may impair placental development due to maternal 
hormonal and inflammatory disturbances. Furthermore, transport of nutrient by the placenta 
could be impaired and result in foetal growth restriction (52). Acute infection and high 
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parasitaemia are associated with stillbirth and preterm delivery whereas chronic placental 
inflammation is associated with foetal growth retardation (51).  
Similarly, anaemia is more common in pregnant women compared to non-pregnant women. 
Although anemia in pregnancy is multifactorial in Sub-Saharan countries (hemodilution, iron 
and folate deficiency, intestinal helminth infection and heamoglobinopathies), the contribution 
of malaria is still significant (53).  
Malaria during pregnancy is caused by the massive accumulation of P. falciparum-infected 
erythrocytes in the placenta. Selective sequestration of infected erythrocytes into the placenta 
occurs through adhesion of members of the PfEMP1 family, which are encoded by the highly 
diverse var gene family (54) to CSA expressed on syncytiotrophoblast cells lining the placental 
intervillous spaces (45). This makes primigravidae particularly vulnerable to placental 
infection with the consequences of LBW and maternal anaemia (43, 44). Specific humoral 
immunity targeting these parasite variants is acquired in later pregnancies and confers 
protection against the consequences of malaria in pregnancy (43, 55). 
3. Diagnosis 
The diagnosis tools currently available for the identification of Plasmodium species include 
thick and thin blood smear microscopy, rapid diagnostic tests (RDTs) and nucleic acid 
amplification techniques such as polymerase chain reaction (PCR) (56, 57) or loop mediated 
isothermal amplification (LAMP) (58). 
3.1 Microscopy  
Light microscopy involves the visualization of the malaria parasites in a thick or thin blood 
smear. Thick blood smear allows the identification of the different species and stages and 
quantification of parasite density. The lower limit of detection is around 50 parasites/µL in 
expert hands (59). Microscopy slides can be preserved for a long time and offer the possibility 
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of quality control and training of lab technicians. However, microscopy requires at least one 
hour to deliver result and requires good equipment and a well-trained staff (60).  
3.2 Rapid diagnostic test 
RDTs are lateral flow immuno-chromatographic antigen-detection tests, which rely on the 
capture of dye-labeled antibodies to produce a visible band on a strip of nitro-cellulose (61). 
Currently, the majority of RDTs in the market detect the P. falciparum specific antigen 
histidine rich protein 2 (PfHRP2) and are relatively more sensitive and heat stable compared 
to lactate dehydrogenase (pLDH) or aldolase-based RDTs (62). The limit of detection for RDTs 
is around 100 parasites/µL (63). RDTs have a number of advantages over microscopy including 
rapidity, simplicity and ease of manipulation. Disadvantages of RDTs include the lack of 
sensitivity in detecting low parasitaemia, the impossibility of quantifying parasite density, the 
difficulty in differentiating Plasmodium species and false-positive results after parasite 
clearance due to the persistence of parasite antigens (64, 65). Furthermore, a number of reports 
have raised the issue of pfhrp2/pfhrp3 gene deletion in circulating field populations resulting 
in false negative PfHRP2-based RDTs that may have serious consequences for diagnosis and 
treatment (66).  
3.3 Polymerase chain reaction 
Nucleic acid amplification tests enable sensitive detection of low density malaria infections 
(below 1 parasite/µL) (67). Nucleic acid tests can be used for qualitative or quantitative parasite 
detection, determination of the multiplicity of infection, genotyping to distinguish 
recrudescence from reinfection, and detection of drug resistance mutations (68).  
The 18S ribosomal RNA gene has unique sequences that enable the identification of all 5 
malaria species infecting humans and is therefore commonly targeted for amplification (69, 
70). 
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Species diagnosis provides therapeutic orientation and allows to anticipate relapses in P. vivax 
and P. ovale infections.  
3.4 Diagnosis of malaria in pregnancy 
The diagnosis of malaria in pregnancy is important because of the devastating consequences 
of the disease in pregnant women. Current diagnostic tools include microscopy, RDTs and 
histology. P. falciparum infections can be difficult to diagnose during pregnancy, particularly 
in asymptomatic women with low peripheral blood parasite density while harbouring parasites 
in the placenta (44, 71). The gold standard for placental malaria diagnosis is histology  of 
placental tissue which allows to distinguish active, chronic and past infections (72). 
4. Malaria prevention and surveillance  
4.1 Prevention 
Different approaches are used to prevent and control malaria. These strategies include vector 
control measures, chemoprevention, early diagnosis and effective treatment of malaria cases. 
Vector control represent an essential component of malaria prevention and includes the use of 
mosquito larvicides, indoor residual spraying (IRS) of houses and insecticide-treated mosquito 
nets (ITNs). Sleeping under a treated mosquito reduces physical contact between mosquitoes 
and humans and provides at the same time an insecticidal effect. In areas of moderate to high 
transmission in Africa, deployment of ITNS reduced all-cause mortality by around 20% in 
under five years old children (73). Together with ITNs, IRS represent the second core vector 
control measure and involves spraying the inside of houses with an insecticide with a long 
residual activity (20).  
 ITN use is recommended as part of the antenatal package provided during pregnancy and leads 
to improved birth outcomes (74). Major challenges remain the resistance of vectors to 
insecticides and the brevity of insecticides’ effect (75). 
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Chemoprevention is currently reserved for children in seasonal malaria transmission areas, 
pregnant women in Africa and for non-immune individuals traveling to endemic areas. 
Seasonal malaria chemoprevention (SMC) is the intermittent administration of full treatment 
courses of an antimalarial to children in areas of highly seasonal transmission during the 
malaria season. Currently, intermittent preventive treatment during pregnancy using 
sulfadoxine-pyrimethamine (IPTp-SP) defined as the administration of curative dose of SP at 
predefined intervals during routine antenatal care as recommended by the World Health 
Organization (WHO). Challenges to IPTp-SP include modest coverage and increasing 
resistance of P. falciparum to SP (76-78). 
4.2 Surveillance 
Improved surveillance for malaria cases and deaths helps ministries of health to determine 
which areas or population groups are most affected while enabling countries to monitor 
changing disease trends. A strong malaria surveillance system also helps a country in designing 
effective health interventions and evaluate the impact of its malaria control programme. The 
annual World malaria report, brings together all the data reported by countries to WHO, 
including their surveillance data (79).  
Recently, renewed focus on global malaria elimination has seen a rapid increase in the 
measurement of key malaria indicators through nationally representative household surveys. 
These malaria indicator surveys (MIS) measure indicators related to the Roll Back Malaria 
(RBM) Global Malaria Action Plan, the Millennium Development Goals (MDG), and the 
President's Malaria Initiative (PMI) targets. Information is collected on the ownership and use 
of insecticide-treated mosquito nets (ITNs), indoor residual spraying (IRS) of insecticides, 
prompt and effective treatment of fever in young children, and the prevention of malaria in 
pregnant women. Most MIS also include biomarker tests for malaria using microscopy or RDT 
and haemoglobin to diagnose anaemia (80). 
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4.3 Vaccines 
More than 35 years of research efforts after the first malaria vaccination trials in the 1970s (81, 
82), Mosquirix also known as RTS,S/AS01 remains the only vaccine that has received a 
positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal 
Products for Human Use (CHMP) (83). 
Difficulty in developing a malaria vaccine could be related to several factors including the 
complex life cycle of the parasite, the genetic diversity of malaria parasites and the absence of 
sterilizing immunity (84, 85). In addition, most of the antimalarial antigens selected as vaccine 
candidates are targets of natural immunity and therefore have significant genetic polymorphism 
(85). 
Depending on the stages of development of the parasite, malaria vaccine candidates can be 
classified into 3 groups: pre-erythrocytic vaccines, blood stage vaccines and "other" vaccines 
including transmission-blocking vaccines and vaccines against malaria during pregnancy.  
4.3.1 Pre-erythrocytic vaccines 
Pre-erythrocytic vaccines target the clinically silent sporozoite and liver stages of P. falciparum 
to prevent hepatocyte invasion and the development of the blood stage. The brief passage of 
sporozoites into the bloodstream before the invasion means that humoral and cellular responses 
are limited at this stage (23). RTS,S is a recombinant vaccine that contains an adjuvant. It is 
composed of a P. falciparum circumsporozoite protein fused with hepatitis B surface antigen 
(rts), and combined with hepatitis B surface antigen (s) (86, 87).  
In phase 3 clinical trials in 11 African countries RTS,S showed a 26% reduction in clinical 
malaria cases in the youngest children and a 36% reduction in children under 17 months (88). 
RTS,S has received a positive opinion from the EMA for children aged 5-17 months and is 
currently being implemented in pilot studies in Ghana, Kenya and Malawi as part of routine 
childhood vaccination (89).  
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Another promising pre-erythrocytic candidate vaccines include irradiated whole P. falciparum 
sporozoites (PfSPZ) or infective sporozoites administered under chemoprophylaxis 
(chemoprophylaxis vaccination or Cvac). Several clinical trials have shown that the whole 
irradiated sporozoite vaccine PfSPZ manufactured by Sanaria® is safe and well tolerated and 
offers promising protection against malaria when administered intravenously (90-94). A Phase 
3 clinical trial to evaluate its efficacy is planned for 2020 in Equatorial Guinea (95). 
4.3.2 Blood stage vaccines 
Erythrocyte vaccines are intended to prevent disease by preventing the invasion of red blood 
cells by merozoites by inducing the production of antibodies against surface antigens of 
Plasmodium-infected erythrocytes. An example of this type of vaccine is the MSP3-based 
vaccine located on the surface of the merozoite, which was associated with a reduction in 
malaria incidence in children in a Phase 2 trial (96).  
Vaccine candidates in this group have generally had little success in clinical trials (97, 98). A 
first generation P. falciparum reticulocyte binding protein homolog 5 (PfRH5) vaccine is being 
tested in clinical trials in Oxford and Tanzania (98). 
4.3.3 Other vaccines 
Transmission-blocking vaccines also known as "altruistic vaccines” induce antibodies against 
gametocytes, thus blocking fertilization (99). P. falciparum Pfs25 antigen is the most targeted 
at this stage (100, 101). 
Vaccines against pregnancy-associated malaria could be useful to prevent placental malaria 
and reduce the burden of the disease during pregnancy. PAMVAC is a vaccine candidate based 
on a recombinant fragment of VAR2CSA, the protein responsible for binding to the placenta 
via CSA. PAMVAC was safe, well-tolerated and induced functionally active antibodies in 
healthy malaria-naive volunteers and will next be assessed in women before first pregnancies 
in endemic areas (102, 103).  
 13 
 
 
The next step in malaria vaccine development will be to combine several vaccine approaches 
with different combinations of antigens from different stages and strains of the parasite. 
The absence of known biological correlate of protection correlates for immunity requires costly 
clinical trials to demonstrate the efficacy of a vaccine (104). Although remarkable progress has 
been made, the development of continuous malaria vaccine is still costly and complex.  
 
Controlled human malaria infection (CHMI), the deliberate inoculation of volunteers with 
Plasmodium spp. sporozoites, is increasingly being used to assess the efficacy of malaria 
vaccines and contributes to accelerate vaccine development (105). Post CHMI, volunteers are 
closely monitored for signs and symptoms of malaria. Parasitaemia in whole blood is closely 
monitored and volunteers are treated before they develop high parasite density. Recently, more 
sensitive quantitative polymerase chain reaction (qPCR) is being used as a primary diagnostic 
test. CHMI has been shown to be safe and very well tolerated and a reliable tool to test vaccines 
and drug’s efficacy in many clinical trials (106, 107). 
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5. Aims of the thesis 
 
Rapid, sensitive and accurate malaria diagnosis is the cornerstone of surveillance and response 
approaches which are needed to reach the final goal of malaria elimination. The overall goal of 
this thesis is to develop novel, molecular-based, sensitive, robust and high-throughput methods 
to monitor Plasmodium spp. infections that might escape RDT-based malaria detection.  
 
Aim 1: develop and evaluate a high-throughput procedure to extract Plasmodium nucleic acids 
including RNA and DNA from malaria rapid diagnostic tests regularly used in malaria indicator 
surveys. 
 
Aim 2: evaluate a novel quantitative polymerase chain reaction-based method for detecting 
hrp2 and hrp3 gene deletions in Plasmodium falciparum field isolates, including mixed 
infections prevalent in sub-Saharan countries. 
 
Aim 3: describe the prevalence of malaria in pregnant women after introduction of intermittent 
preventive treatment on Bioko Island using RDTs collected during the malaria indicator survey 
conducted on Bioko Island, Equatorial Guinea in 2018. 
 
Aim 4: Understand the impact of HIV-co-infections on asexual blood stage parasitemia during 
controlled human malaria infection in Tanzanian volunteers. 
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Chapter 2 
 
Tools and techniques for high-throughput molecular malaria surveillance 
 
This chapter contains the following manuscript submitted to Scientific Reports: 
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Hoffman, Carlos Cortes Falla, Wonder P. Phiri, Carl Maas, Guillermo A. Garcia, Marcel 
Tanner and Claudia Daubenberger.  
Molecular malaria surveillance using a novel protocol for extraction and analysis of 
nucleic acids retained on used rapid diagnostic tests 
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Abstract 
The use of malaria rapid diagnostic tests (RDTs) as a source for nucleic acids that can be detected by 
nucleic acid amplification techniques has several advantages, including the small amount of blood 
and cost-effectiveness regarding sample collection as well as simplified storage and shipping condi-
tions at room temperature. We have developed systematically and evaluated extensively a procedure 
to extract total nucleic acids from used malaria RDTs. The co-extracted DNA and RNA molecules 
from small volumes of dried blood retained on the RDTs allows detection and quantification of P. 
falciparum parasites from asymptomatic patients with parasite densities as low as 1 Pf/µL blood using 
reverse transcription quantitative PCR. Around the extraction protocol, we have developed the Ex-
traction of Nucleic Acids from RDTs (ENAR) approach, a complete workflow for large-scale molec-
ular malaria surveillance. Using RDTs collected during a malaria indicator survey, we demonstrated 
that ENAR provides a powerful tool to analyse nucleic acids from thousands of RDTs in a standard-
ized and high-throughput manner. We found several, known and new, non-synonymous single nucle-
otide polymorphism in the propeller region of the kelch 13 gene among isolates circulating on Bioko 
Island, Equatorial Guinea. 
 
Keywords  
Nucleic Acid Extraction, Molecular Malaria Surveillance, Rapid Diagnostic Test (RDT), Reverse 
Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), Artemisinin resistance, kelch 13  
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Introduction 
 
Malaria remains a global public health issue with an estimated 228 million cases resulting in 405’000 
deaths in 2018 [1]. P. falciparum (Pf) is the most pathogenic malaria species accounting for the vast 
majority of malaria cases and deaths. Malaria surveillance, the continuous and systematic collection, 
analysis and interpretation of epidemiological data, is the basis of intervention programs to control 
malaria and provides the framework for effective allocation of resources [2]. A critical surveillance 
measure, which reflects the malaria transmission intensity closely, is the parasite rate; the proportion 
of the population found to carry parasites in their peripheral blood [3,4]. Malaria rapid diagnostic 
tests (RDTs) have become the most widely used technique to measure parasite rates in endemic coun-
tries. In sub-Saharan Africa, RDTs have almost completely replaced light microscopy for malaria 
diagnosis, with an estimated 75% of malaria tests conducted using RDTs in 2017 [1]. Among the 
advantages of RDTs are the relatively low costs, fast result turnaround time, wide availability and 
simplicity in use. However, there are also disadvantages, which include the rather low sensitivity, 
which results in poor performance among asymptomatic individuals [5] and the widespread emer-
gence of pfhrp2 deletions in certain regions [6]. 
Nucleic amplification techniques (NATs), such as polymerase chain reaction (PCR), do not only show 
higher sensitivities than RDTs [5,7] they also allow further characterization of Pf isolates using mo-
lecular markers. Surveillance of drug-resistant Pf strains, based on analysis of resistance-associated 
molecular markers, is a widely used and valuable epidemiological tool [8]. In sub-Saharan Africa, 
treatment of malaria relies heavily on artemisinin-based combination therapy (ACT) and implemen-
tation of surveillance programs for early detection of emerging artemisinin resistant Pf strains will be 
key to prevent the spread across the continent [9]. Artemisinin resistant Pf strains were first reported 
in Cambodia [10,11] and remain a public health concern in South East Asia, but have not yet been 
found to be widespread in Africa, South America or Oceania [12]. Non-synonymous mutations in the 
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propeller region of the Pf kelch 13 gene (pfk13) were discovered as molecular markers for artemisinin 
resistance [13].  
The use of the blood retained on RDTs as as a source for nucleic acids (NAs) that can be used as an 
input for NAT-based resistance markers screening would have several advantages, including the sim-
plicity and cost-effectiveness regarding sample collection as well as simplified storage and shipping 
conditions under room temperature (RT). Over the past decade, several reports have been published 
describing the use of DNA extracted from used RDTs for molecular analysis of malaria parasites 
(studies summarized in Table S1) [14–24]. However, most studies that tried to address the question 
of using RDT as source of DNA were conducted with small sample sizes and focused rather on 
demonstrating the feasibility of extracting DNA than fitting this approach for molecular surveillance 
of malaria parasites at larger scale. We identified three key areas, which are critical in order to develop 
a surveillance tool based on molecular analysis of used RDTs: i) accessing a representative collection 
of RDTs and effective selection and sorting strategies for RDTs of interest. ii) high-throughput ex-
traction and analysis of NA from RDTs with minimal hands-on time and focus on reproducibility and 
quality control throughout the entire extraction process. iii) increasing recovery of Pf NAs during 
extraction process in order to include asymptomatic individuals with low parasite density infections. 
This report outlines a strategy and protocols for collecting, sorting and processing RDTs to extract 
the retained NA at large-scale in order to screen for single nucleotide polymorphism (SNP) in an 
artimisinin-associated drug resistance marker among thousands of healthy, malaria asymptomatic in-
dividuals. We developed systematically and evaluated extensively a procedure to extract NA from 
RDT. The “Extraction of Nucleic Acids from RDTs” (referred to as ENAR) approach is supported by 
custom-made software solutions allowing to analyse thousands of RDTs in a standardized, reproduc-
ible and high-throughput manner.  
We implemented the ENAR approach within the 2018 malaria indicator survey (MIS) conducted on 
Bioko Island, Equatorial Guinea. Island-wide interventions have resulted in a substantial reduction in 
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malaria, achieving a reduction in parasitaemia of over 75% over 13 years [25]. Despite these achieve-
ments, malaria transmission remains stable and recently a Pf isolate of African origin with artimisinin-
resistance, including a novel non-synonymous mutation in pfk13, was identified in a 43-year-old man 
returning to China from Equatorial Guinea [15]. 
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Material and methods 
 
Pf reference samples 
Pf reference samples were used to test the performance of the ENAR procedure. Experiments with Pf 
reference samples were conducted using CarestartTM HRP2/pLDH Combo RDTs (Access Bio, Inc., 
Somerset, NJ, USA). Serial dilutions of the WHO International Standard for Pf DNA Nucleic Acid 
Amplification Techniques (NIBSC code: 04/176, herein referred to as PfIS) [27] were used to quan-
tify Pf parasitaemia by (RT)-qPCR. Whole blood was spiked with different parasite densities, ranging 
from 10’000 to 0.1 Pf/µL and 5 µL of this suspension applied onto RDT.  
Additionally, ten-fold serial dilutions, ranging from 10’000 to 0.1 Pf/µL, of freshly cultured Pf strains 
PfNF54, PfDD2 and PfHB3 were prepared and 5 µL were applied onto RDTs. 5 µL of stage V game-
tocytes were obtained from in vitro parasite culture as described previously [28]. RDTs probed with 
these stage V gametocytes were extracted using the ENAR protocol after a three-week storage period 
at RT.  
 
School-based survey in Mkuranga district 
CarestartTM HRP2/pLDH Combo RDTs were used to determine the parasite rate among asymptomatic 
children from three primary schools in the Mkuranga district of Coastal Tanzania. Extraction protocol 
A, which is based on the Quick-DNA™ Miniprep Kit (Zymo Research Corporation, Irvine CA, 
USA), was used to extract DNA from a total of 190 RDTs collected during this school-based survey. 
Pf was detected by amplifying the acidic terminal sequence of the var genes (PfvarATS) [29]. 
 
Sample collection, analysis and storage during CHMI studies 
RDTs were collected during two CHMI studies conducted to evaluate Sanaria’s PfSPZ Vaccine in 
Bagamoyo, Tanzania (Clinical Trials.gov registration numbers NCT02613520 and NCT03420053, 
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respectively). The first CHMI was conducted in 2016 (referred to CHMI-1) the second CHMI was 
conducted in 2018 (referred to CHMI-2). Fresh venous whole blood collected in EDTA tubes was 
analysed by RDTs within 45 min after blood collection. During CHMI-1, 20 µL was applied to 
BinaxNOW® Malaria RDT (Alere, Cologne, Germany) and during CHMI-2, 5 µL was applied to 
CarestartTM HRP2/pLDH Combo RDT. The RDTs were read according to the manufacturers guide 
and then stored in a box at RT until extraction of NA. 
The same samples were used to monitor parasitaemia during CHMI by thick blood smear microscopy 
and qPCR as described elsewhere [30,31]. All samples were processed and analysed at the laborato-
ries of the Bagamoyo branch of the Ifakara Health Institute in Tanzania. 
 
Malaria indicator survey on Bioko Island, Equatorial Guinea  
The 2018 Malaria indicator survey was carried out between August and October 2018 on a repre-
sentative sample of 13’505 individuals from 4774 households selected from all communities across 
Bioko Island. All consenting permanent residents and short-term visitors were tested for malaria using 
the CareStartTM Malaria HRP2/pLDH Combo RDT. Used RDTs were stored at RT in plastic bags 
containing desiccants and transported to the Swiss Tropical and Public Health Institute for further 
molecular analysis. 
 
Nucleic acid extraction methods from RDTs 
The cassettes of the RDTs were opened, the entire RDT strip removed, and cut into four small pieces 
in order to fit into a 1.5 mL micro-centrifuge tube. A set of cleaned forceps and scissors were used 
with special attention given to prevent cross-contamination between samples. After processing a sam-
ple, scissors and forceps were cleaned in 10% sodium hypochlorite and wiped with ethanol sprayed 
tissues and dried before processing the next sample. The four nucleic extraction protocols tested, 
named A-D, were all based on silica columns. 
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Protocol A – ZR Quick-DNA™ Miniprep Kit: The protocol is based on the Quick-DNA™ Miniprep 
Kit (Zymo Research Corporation, Irvine CA, USA). Briefly, 1 mL of Genomic Lysis Buffer was 
added to the pre-cut RDT strip in a 1.5 mL micro-centrifuge tube and incubated at 95 °C for 20 
minutes. The mixture was then transferred onto the extraction column and the manufacturers guide 
was followed for extraction. DNA was eluted in 50 µL of DNA Elution Buffer.  
Protocol B – ZR Quick-DNA™ Miniprep Plus Kit: The protocol is based on the Quick-DNA™ Min-
iprep Plus Kit (Zymo Research Corporation, Irvine CA, USA). Briefly, 600 μL of Solid Tissue Buffer 
(Blue) and 40 μL of Proteinase K was added to the pre-cut RDT strip in a 1.5mL micro-centrifuge 
tube and incubated at 55 °C for 60 minutes. The supernatant was transferred to a clean 1.5 mL micro-
centrifuge tube and 640 μL of Genomic Lysis Buffer was added and mixed thoroughly. The mixture 
was then transferred onto the extraction column and the manufacturers guide was followed for ex-
traction. DNA was eluted in 50 µL of DNA Elution Buffer.  
Protocol C – NukEx Pure RNA/DNA Kit: The protocol is based on NukEx Pure RNA/DNA Kit 
(Gerbion GmbH, Kornwestheim, Germany), which co-extracts DNA and RNA. Briefly, a working 
solution of 500 μL of Binding Buffer, 4 μL of Poly A and 50 μL of Proteinase K was added to the pre-
cut RDT strip in a 1.5 mL micro-centrifuge tube and incubated at 60 °C for 10 minutes. The superna-
tant was transferred onto the NukEx Spin Column and the manufacturers guide was followed for 
extraction. Total NA were eluted in 50 µL of Elution Buffer. 
Protocol D – Zainabadi et al. extraction method for DBS: The protocol is based on a recently pub-
lished extraction protocol for total NA from dried blood spots [32]. Identical buffer compositions 
were used, and the protocol was adapted to extraction of NA from RDT strips. Briefly, the pre-cut 
RDT strip was incubated in 900 µL lysis buffer at 60 °C for 2 hours. The supernatant was transferred 
onto Omega HiBind RNA Mini Columns (Omega Bio-Tek, Norcross, USA) and NA extracted as 
described. NA were eluted in 50 µL of Elution Buffer (Quick-DNA™ Miniprep Kit, Zymo Research 
Corporation, Irvine CA, USA). 
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High-throughput extraction protocol of NAs from RDTs (ENAR protocol) 
We adapted protocol D to extract NA from used RDTs in a high-throughput manner. The main mod-
ification included a horizontal incubation of the entire uncut RDT strip by using sterile, RNase-
/DNase-free 12-channel reservoirs (Axygen, Corning Inc, USA) and switching to a 96-well format 
for extraction. By removing the cutting step, the hands-on time during the extraction process is sig-
nificantly reduced, and the risk of cross-contamination by carryover during the cutting is minimized. 
Up to eight 12-channel reservoirs, with a total of 96 samples, were processed in one batch. Lysis was 
conducted by adding 900 µL lysis buffer to each RDT strip placed in the 12-channel reservoir fol-
lowed by incubation at 60 °C for 2 hours with gentle shaking. All supernatants were then transferred 
to Omega E-Z 96 wells DNA plates (Omega Bio-Tek, Norcross, USA), washed with Wash Buffer 1 
and 2 and finally eluted into a 96 well plate (DNA LoBind Plates, Eppendorf) with 50 µL pre-warmed 
(60 °C) Elution Buffer (Zymo Research Corporation, Irvine CA, USA). With these adaptations to the 
protocol, NA from 96 RDTs are extracted in about three hours, with minimal hands-on time needed. 
One positive control (RDT spiked with 5 µL blood containing 200 Pf/µL) and one negative control 
(Lysis Buffer only) were included with each extraction plate to control for plate-to-plate consistency 
and cross-contamination. A standard operating procedure (SOP) for ENAR can be found as supple-
mentary file 1. 
 
Detection and quantification of Plasmodium spp. parasites  
We used the PlasQ assay, a multiplex qPCR assay for Plasmodium spp. and Pf detection and quanti-
fication to analyse the NA extracted from RDTs [31]. The PlasQ assay targets the Pan-Plasmodium 
18S DNA and RNA (Pspp18S) [33,34] and the Pf-specific acidic terminal sequence of the var genes 
(PfvarATS) [29]. The human rnasep gene (HsRNaseP)  [33]  served as an internal control to assess 
the quality of NA extraction and qPCR amplification. To run the PlasQ as a RT-qPCR assay, targeting 
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both DNA and RNA templates, we added 1x Luna WarmStart RT Enzyme Mix (New England Bi-
olabs, Ipswich, USA) and did start the qPCR program with a reverse transcription step at 55 °C for 
15 min. All qPCR and RT-qPCR assays were run on a Bio-Rad CFX96 Real-Time PCR System (Bio-
Rad Laboratories, California, USA). Samples were analysed in duplicates with positive (PfNF54 
DNA), negative (malaria negative individual) and non-template (molecular biology grade H2O) con-
trols added to each qPCR run.  
 
Multiplex pre-amplification of Plasmodium spp. DNA 
The Plasmodium spp. 18S rDNA and pfk13 genes of all PlasQ positive samples were amplified in a 
multiplex reaction by conventional PCR. Briefly, 3 μL of extracted NAs were amplified in a total 
volume of 20 μL using 1x HOT FIREPol® MultiPlex Mix (Solis Biodyne, Tartu, Estonia). Using 0.25 
µM of the published primers, AGT GGA AGA CAT CAT GTA ACC AG and CCA AGC TGC CAT 
TCA TTT GT, 986 bp of the pfk13 propeller region were amplified [26]. Simultaneously, 1407-1469 
bp of the pan-Plasmodium 18S rDNA were amplified using 0.5 µM of GRA ACT SSS AAC GGC 
TCA TT [35]  and AGC AGG TTA AGA TCT CGT TCG [33]. The conditions of the multiplex PCR 
were the following: 95 °C for 12 minutes; 25 cycles of 95 °C for 20 seconds, 57 °C for 40 seconds 
and 72 °C for 1 minute 45 seconds; and 72 °C for 10 minutes. 
 
Detection of  gametocytes and Plasmodium spp. species identification 
Gametocyte-specific RT-qPCR assay: A previously published RT-qPCR assay for identification of Pf 
gametocytes based the PF3D7_0630000 transcript was used [36].  Briefly, 2 µL of extracted NA were 
added to 8 µL reaction mix consisting of 0.6 µM of primers, 0.3 µM probe and Luna® Universal 
Probe One-Step RT-qPCR Kit (New England Biolabs, Ipswich, USA). The qPCR program included 
reverse transcription for 15 min at 53 °C, followed by polymerase activation for 1 min at 95 °C and 
45 cycles with 15 s at 95 °C and 45 s at 53 °C. 
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Plasmodium spp. species identification: Non-falciparum Plasmodium species identification based on 
the 18S rDNA gene was performed. 2 µL of the product from the Plasmodium spp. multiplex pre-
amplification were added to the master mix containing 1x Luna® Universal Probe qPCR Master Mix, 
0.8 µM forward (GTT AAG GGA GTG AAG ACG ATC AGA) and 0.8 µM reverse primers (AAC 
CCA AAG ACT TTG ATT TCT CAT AA) to amplify a 157- to 165-bp segment of the Plasmodium 
spp. 18S rDNA gene [37]. Species-specific probes were selected to differentiate between the species. 
P. malariae was detected using a Yakima Yellow-labelled MGB probe (CTA TCT AAA AGA AAC 
ACT CAT) [38], P. ovale spp. using a novel designed Texas Red-labelled and LNA-modified probe 
(GGA [LNA-A]AT [LNA-T]TC TTA GAT TGC TTC CT[LNA-T] CAG), P. vivax a Cy5-labelled 
probe (GAA TTT TCT CTT CGG AGT TTA) [39] and P. knowlesi a Cy5-labelled probe (CTC TCC 
GGA GAT TAG AAC TCT TAG ATT GCT) [40]. The conditions for the qPCR were: 95 °C for 3 
minutes and 45 cycles of 95 °C for 15 seconds and 57 °C for 45 seconds. 
 
Genotyping of pfk13 propeller region 
In a second PCR reaction with a 15 μL total volume, 1.5 μL of the product from the Plasmodium spp. 
multiplex pre-amplification was amplified using 1x HOT FIREPol® MultiPlex Mix (Solis Biodyne, 
Tartu, Estonia) and 0.33 μM forward (TGA AGC CTT GTT GAA AGA AGC A) and reverse (TCG 
CCA TTT TCT CCT CCT GT) primers. Except for an annealing temperature of 58 °C, the PCR 
conditions were similar to the first reaction. The 798 bp product of the second PCR was evaluated 
using agarose gel electrophoresis and samples which failed amplification were repeated. Amplicons 
were sequenced by Microsynth (Microsynth AG, Balgach, Switzerland). 
 
Data analysis and statistics 
All (RT)-qPCR assays were run in duplicates and initial data analysis of the (RT)-qPCR data was 
conducted using CFX Maestro Software (Bio-Rad Laboratories, California, USA). In case of one 
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replicate interpreted as positive and the other replicate negative, then the assay had to be repeated and 
the result was considered positive if two positive replicates were obtained out of the total four repli-
cates. All (RT)-qPCR data generated were managed and analysed by a custom-designed laboratory 
management and information system named ELIMU-MDx [41]. The ELIMU-MDx platform supports 
automated quality control, management and analysis of qPCR data. Oligo design and sequence anal-
ysis was performed using Geneious Prime 2019.1.1 (https://www.geneious.com). Statistical analysis 
and visualization of data was conducted using R version 3.5.1 based on packages dplyr, ggpubr, 
ggplot2, gridextra, reshape2 and scales.  
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Results 
 
Blood stored on RDTs is a source of Pf DNA 
First, we conducted a literature search of reports describing the use of NA extracted from RDTs as 
input templates for NAT based detection of malaria parasites (Table S1). A total of 11 studies were 
published between 2006 and 2019. All studies were limited to the extraction of DNA and used a 
variety of different extraction methods. Most extraction protocols were based either on the Chelex 
method (n=7) or silica column based DNA extraction kits (n=6). One study extracted DNA from the 
entire RDT strip, all other studies used only predefined fragments of the RDT strip. These previous 
studies demonstrated that Pf DNA can be recovered from RDTs and amplified by NATs. Several 
studies genotyped drug resistance associated markers using Sanger or next generation sequencing.  
As the majority of these studies extracted DNA from RDTs of febrile clinical malaria cases, indicating 
high parasite densities, we first conducted a study to test feasibility of detecting Pf DNA from RDTs 
of asymptomatic individuals. We employed RDTs collected in a malaria survey conducted among 
asymptomatic children from three primary schools in the Mkuranga district of Coastal Tanzania. DNA 
was extracted from 190 RDTs and Pf DNA was recovered from 90.8% (59/65) of PfHRP2-positive, 
from 100% (5/5) of PfHRP2/pLDH-positive and from 11.7% (14/120) negative RDTs (Fig 1A). 
Encouraged by the outcome of the school-based survey, we aimed to improve the extraction method 
from RDTs further. As a proxy for the amount of extracted NAs, the Cq value of the human rnasep 
gene (HsRNaseP target), which is the internal control of the previously published PlasQ assay, was 
used to assess the overall performance of four different extraction procedures (Fig 2B). Side by side 
comparison of the four extraction procedures, named Protocol A-D, confirmed the superior perfor-
mance of protocol B and D. Taking the costs and the fact that protocol D co-extracts RNA into con-
sideration, we decided to focus on development of protocol D, which was subsequently renamed to 
ENAR (Extraction of Nucleic Acids from RDTs). In order to identify the part of the RDT strip with 
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most Pf NA accumulated, we analysed the sample pad (proximal part), the detection area (middle 
part) and the absorption pad (distal part) using ENAR. In RDTs probed with fresh blood, Pf NAs are 
found in all three parts, with more than 87% of total DNA enriched in the middle part. RDTs probed 
with frozen blood that is associated with red blood cell lysis resulted in an equal distribution of NA 
along the entire RDT strip (Fig S1).  
 
Detection and quantification of Pf parasites based on ENAR protocol 
We then evaluated the ENAR protocol with cultured Pf strains including the strains PfDD2, PfHB3 
and PfNF54 by preparing ten-fold serial dilutions in whole blood with parasite densities correspond-
ing to 0.1 – 1000 Pf/µL. RDTs were probed with 5 µL of diluted cultures, the NA extracted by ENAR 
and analysed by qPCR and RT-qPCR (Fig 1C). Only the RT-qPCR assay resulted in detection of all 
three strains with the 1 Pf/µL parasite density. Furthermore, the Pspp18S based RT-qPCR assay even 
detected two (PfDD2 and PfNF54) out of the three Pf strains at density of 0.1 Pf/µL. This result 
demonstrates that the ENAR clearly co-extracts DNA and RNA. The Pf 18S ribosomal RNA, detected 
by the Pspp18S RT-qPCR assay, is highly and constant expressed during the life cycle of the parasite 
[42,43],  while the acidic terminal sequence of the var genes (PfEMP1), detected by the PfvarATS 
assay, has lower RNA levels [44]. The ability of the ENAR protocol to co-extract DNA and RNA was 
also demonstrated with the following experiment. Five µL of an in vitro generated stage V gametocyte 
culture was applied onto RDTs and stored at RT for three weeks before NA were extracted by ENAR. 
The gametocyte-specific transcript PF3D7_0630000 was reverse transcribed and amplified using a 
published assay which does not require DNase treatment for specific detection of gametocytes [36]. 
Extracted NA from 5 μL undiluted and 1:100 diluted stage V gametocytes amplified specifically the 
gametocyte marker, while the control without reverse transcription step did not result in amplification 
(Fig S2). 
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The PfIS, an international standard with known parasite density, was used to explore the feasibility 
of quantifying Pf parasites extracted by ENAR. In total, 51 individual RDTs containing 5 µL PfIS 
with different parasite densities, ranging from 0.1 to 10’000 Pf/µL of the PfIS, were prepared. A high 
reproducibility and a reversed correlation between parasite densities and Cq values were observed for 
both targets, the Pf specific PfvarATS and the pan-Plasmodium target Pspp18S (Fig 1D). Based on 
the slope, RT-qPCR efficiencies of 75.4% and 124.3% were calculated for PfvarATS and Pspp18S, 
respectively. RDTs negative for PlasQ assay amplification (Cq > 45, colored in red) carried mostly 
dilutions representing parasite densities ≤ 1 parasite/µL. Two exceptions were observed where the 
Pspp18S assay failed to amplify two RDTs probed with higher parasitaemia levels (5 and 10 Pf/µL, 
respectively). RDTs probed with 1 parasite/µL were detected in 4 (PfvarATS) and 7 (Pspp18S) out of 
10 RDTs tested.  
In summary, based on experiments conducted with standardized Pf reference samples we conclude 
that ENAR is able to recover DNA and RNA, which results in an increased sensitivity of the RT-
qPCR compared to the qPCR-based detection methods. The lower limit of detection (LOD) for RT-
qPCR-based amplification of NA from RDTs is around 1 Pf/µL, although 10x lower parasitaemia 
levels can be detected as demonstrated with freshly cultured Pf parasites. RDTs are a reliable source 
of NA and extraction by ENAR followed by analysis using RT-qPCR assays allows quantification of 
Pf parasites. 
 
Evaluation of ENAR protocol using Controlled Human Malaria Infection studies as a platform 
Blood collected from volunteers undergoing Controlled Human Malaria Infection (CHMI) studies 
represent well-characterized samples since the parasite strain, the timing and dosing of infection is 
known. Therefore, blood samples collected from volunteers undergoing CHMI are highly suitable to 
develop and validate novel malaria diagnostic tools [45]. 
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The ENAR protocol was evaluated with venous blood samples collected during CHMIs assessing the 
efficacy of Sanaria’s PfSPZ Vaccine in clinical trials in Bagamoyo, Tanzania in malaria pre-exposed 
volunteers. RDTs were probed with blood and stored as part of two CHMIs, the first CHMI was 
conducted in 2016 (CHMI-1) and the second CHMI in 2018 (CHMI-2). As part of the standard diag-
nostic procedures during the CHMIs, whole blood was collected in EDTA tubes and DNA was ex-
tracted from a total of 180 µL whole blood. A DNA-based qPCR assay was run and parasitaemia 
quantified (defined as WB-qPCR). Parasite densities as low as 0.05 Pf/µL are detected with the WB-
qPCR protocol. During both CHMIs fresh blood from asymptomatic subjects collected 9 to 18 days 
post CHMI was tested with RDTs (Table 1). CHMI-1 and CHMI-2 used two different types of RDTs 
which required 20 µL and 5 µL of whole blood, respectively. RDTs collected during CHMI-1 were 
stored for 605 days on average (storage defined as > 18 months), while RDTs collected during CHMI-
2 were stored for 18 days on average (< 1 month) before processing following the ENAR protocol. 
During the entire storage period, RDTs were kept at RT in a closed box and protected from light. NA 
were extracted from the RDTs using the ENAR protocol and parasites were detected and quantified 
by RT-qPCR using the PlasQ assay. 
 
Table 1. Overview of blood samples collected during two CHMIs and stored on RDTs. 
 
Impact of long-term storage on detection rate of parasite NA extracted by ENAR 
First, we analysed the impact of RDT storage time on the parasite detection rates. Long-term storage 
(> 18 months) negatively affects the Pf detection rate in samples with parasite density between 1 and 
10 Pf/µL in blood used to probe the RDT but has no negative impact on samples with initial parasite 
density greater than 10 Pf/µL (Fig 2A). Long-term storage negatively affects rather the detection rate 
based on the Pspp18S target (33% vs 100%, Fisher’s exact test p = 0.06) than the PfvarATS target 
(66% vs 100%, Fisher’s exact test p = 0.46). Interestingly, the parasite densities estimated from RDTs 
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with shorter storage time (< 1 month) are closer to the reference parasite densities assessed by WB-
qPCR using 180 µL freshly prepared blood than the estimates from RDTs with longer storage time 
(> 18 months) (Fig 2B). This is an additional indicator that NAs conserved on RDTs might undergo 
degradation over time.  
 
Clinical sensitivity and parasite quantification based on ENAR approach 
If the data of both CHMIs is combined, the overall detection rate was 54% for the ENAR-based RT-
qPCR when compared to WB-qPCR, which was significantly higher than detection by microscopy 
(9%) or PfHRP2 antigen capture by RDT (12%) using the identical samples. 
In order to understand the contribution of RNA to the detection rates in this clinical sample set, we 
decided to compare RT-qPCR with qPCR. Detection rates of RT-qPCR in relation to parasite densitiy 
reveals an improved diagnostic performance over the whole range of Pf densities compared to qPCR 
(Fig 2C). RT-qPCR is significantly more sensitive than qPCR for the Pspp18S assay (27% vs 47%, 
McNemar test p=0.0026), but not for the PfvarATS assay (47% vs 47%, McNemar test p=1.0). Inter-
estingly, among the long-term stored RDTs collected in 2016, the detection rate of the Pspp18S assay 
was also significantly higher for RT-qPCR compared to qPCR (52% vs 22%, McNemar test p =0.01). 
Even after long-term storage a significant proportion of (fragmented) RNA can be still extracted and 
used for RT-qPCR amplification. 
Parasite densities determined by WB-qPCR versus densities obtained with ENAR-based RT-qPCR 
method showed significant positive correlation underlying the quantitative character of our approach 
(Fig 2D). The correlation was stronger with the PfvarATS assay (r2 = 0.72) than with the Pspp18S 
assay (r2 = 0.39).  
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Implementation of ENAR protocol within malaria indicator survey 
Next, we implemented the ENAR approach within a malaria indicator survey in which we aimed to 
screen for SNP in the pfk13 propeller region to study the prevalence and type of mutations potentially 
associated with artemisinin resistance. We started our project with the 2018 malaria indicator survey 
on Bioko Island which included more than 13’000 individuals (Fig 3A). Instead of disposing the 
RDTs after probing and reading, used tests were labeled with a barcode with the intention to connect 
each RDT with other survey data collected in questionnaires (Fig 3B). For each of these barcode-
labeled RDTs an extra informed consent for molecular analysis was obtained from the participants or 
their legal guardians. For the sorting and selection of distinct RDTs that we wanted to analyse, we 
developed the RDTselect app (https://github.com/Sparclex/barcode-value-finder), a browser-based 
mobile phone application which identifies barcode-labeled RDTs based on an input list containing all 
barcodes of a certain selection (Fig 3C). To enable tracking of an individual RDT throughout the 
ENAR extraction process the RDTallocator app (https://github.com/Sparclex/position-allocator) was 
programmed.  The barcodes are scanned with a mobile phone camera and the RDTallocator app allo-
cates the associated RDT strip to the next available position in a 96-well plate (Fig 3C). Next, after 
opening the RDT shell the entire uncut RDT strip is removed with sterile, single use forceps (Fig 3D), 
incubated with lysis buffer in a 12-well long-format plate (Fig 3E), and finally NA are extracted with 
a high-throughput 96-well format of the ENAR protocol (Fig 3F). All extracted samples undergo 
initial screening for presence of Plasmodium spp. parasites and quality control using the PlasQ RT-
qPCR assay (Fig 3G). All RT-qPCR data generated were managed and analysed by a custom-designed 
laboratory management and information system. ELIMU-MDx is designed for automated quality 
control, management and analysis of qPCR data [41] (Fig 3H). Samples positive for Pf were subjected 
to amplification and sequencing of pfk13 for identification of SNPs associated with drug resistance 
(Fig 3I). 
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A total of 2690 out of 13’270 (20.3%) RDTs were extracted by ENAR and analysed for Plasmodium 
spp. parasites by RT-qPCR. The demographic information of the entire MIS population and the se-
lected volunteers for the molecular analysis are given in Table 2. Only volunteers with body temper-
ature < 37.5 °C were included. Intentionally, in our sample set volunteers with a positive RDT and 
pregnant women are over-represented.  
 
Table 2. Demographic information of MIS participants. 
 
Malaria infections among asymptomatic MIS participants are characterized by Pf infections 
with mainly low parasite densities 
Applying the approach described in Figure 3, 30.8% (828/2690) of analysed RDTs were tested posi-
tive for Plasmodium spp. NA (Table 3). A qPCR-based species identification revealed that 92.9% 
were Pf, 4.0% P. malariae and 1.0% P. ovale spp. No P. vivax or P. knowlesi NA were found. In this 
asymptomatic population the Pf infections had on average parasite densities of 29.2 Pf/µL, with den-
sities being the highest among children below the age of five years (Fig 4a).  The rather low parasi-
taemia levels of asymptomatic individuals in combination with the little amount of blood available 
have implications for pfk13 genotyping. Samples with parasitaemia levels below 50 Pf/µL are being 
rarely amplified successfully for pfk13 sequencing (Fig 4b). In order to increase the efficiency of 
pfk13 genotyping process from RDTs, pre-selection based on their RDT result is advised. For exam-
ple, 84.5% of RDTs positive for both, PfHRP2 and pLDH, carried parasite densities high enough to 
result in successful amplification of the pfk13 propeller region.  
 
Table 3. ENAR-based identification of malaria parasites using PlasQ RT-qPCR assay. 
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Low prevalence of SNPs in the pfk13 propeller region among Pf parasite isolates on Bioko  
Sequence analysis of the pfk13 propeller region revealed a low prevalence of SNPs (Table 4). 97.6% 
(283/290) of Bioko’s Pf isolates carried the wildtype allele. Two isolates had the A578S and one the 
V589I non-synonymous SNPs, which have been described in sub-Saharan Africa before [12,46] and 
which are not associated with artemisinin resistance [47]. The P553L SNP was first described in 
Cambodia [13]. This SNP has previously been found at low prevalences in East Africa, in Kenya and 
Malawi [48] and was recently also found in an isolate from a Chinese national returned from Angola 
[49]. To our knowledge the V517I SNP has never been described before. Compared to the other three 
known SNPs, the V517I SNP had the lowest PROVEAN [50] score, indicating no or neutral effects 
on the biological function of the kelch 13 protein. Two synonymous SNPs, namely, V510V and 
C469C, were also found. 
 
Table 4. Pfk13 propeller polymorphisms observed in MIS population on Bioko Island.  
                       36 
Discussion 
 
This report presents the development of an approach for large-scale, high-throughput and cost effi-
cient molecular surveillance of malaria parasites based on extraction of NA from RDTs. During the 
development of ENAR, special attention was given to the evaluation of its reproducibility and the 
impact of long-term storage on the detectability of the NAs. Using samples from CHMI studies as a 
standardized platform allowed us to conclude that NAs can be reliably recovered and amplified from 
RDTs, even after long-term storage at RT. The small amount of blood in combination with low para-
site density is a challenge when it comes to detecting Pf in asymptomatic patients. Therefore, we 
aimed to maximize the amount of NA recovered from RDTs by expanding the pool of possible target 
molecules for detection to RNA by using RT-qPCR. Even after a storage period of over 18 months at 
RT the detection rate of the RT-qPCR assay was still significantly higher compared to qPCR only, 
indicating long-term preservation of DNA and RNA. 
We aimed to transform the ENAR approach into an amendable tool for larger scale surveillance stud-
ies by increasing extraction and analysis throughput. The ENAR approach was successfully integrated 
into the 2018 MIS on Bioko Island. More than 13’000 individuals gave their extra consent for storage 
and molecular analysis of their RDT. This high acceptance rate was also described by others [21] and 
can be attributed to the convenient way of blood collection by finger prick and the small blood vol-
ume, usually 5 to 10 µL, applied onto RDTs. With a total of 2750 RDTs, we analysed blood from 
more than 20% of MIS participants. This was made possible by the development of custom-made 
software solutions for sorting and identification of RDTs and by reducing the processing time signif-
icantly by using the entire RDT strip instead of cutting it into pieces.  
Robust (quantitative) data, as generated by ENAR, in combination with a large-scale MIS adds sub-
stantial value to our understanding of malaria endemicity on Bioko Island without the need of con-
ducting additional expensive and time consuming epidemiological studies. We did not find evidence 
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for presence of P. vivax on Bioko Island. This is contradictory to previous studies when a surveys 
carried out in 1996 and 1998 found two [51] and one [52] case of P. vivax, respectively. 
We decided to screen for SNPs in the propeller region of the pfk13 gene among asymptomatic indi-
viduals to obtain data of possible artemisinin resistant Pf strains circulating on the island. We found 
that 1.7% (5/290) of the analysed Pf isolates had non-synonymous SNPs in the pfk13 propeller region, 
which is comparable to prevalences found in other African countries [46]. Among the five isolates 
with non-synonymous SNPs, two isolates had the A578S, one the V589I, one the P553L and one the 
V517I SNP. The A578S and V589I allele had been reported in the region already [53,54], while with 
V517I we found one new allele, which has not been reported yet at all. Interestingly, the P553L SNP 
is the only mutation we found which was previously associated with delayed parasite clearance [12]. 
Although the prevalence of pfk13 SNPs seems to be low at the moment, the spread of Pf parasites 
with pfk13 SNP needs to be closely monitored. An molecular surveillance approach as presented may 
offer an unique opportunity to support policy makers regarding the choice and change of drugs for 
malaria treatment [55].  
Based on the presented results we conclude that ENAR provides a powerful tool for molecular malaria 
surveillance and could be reliably used for retrospective quantitative and in-depth molecular studies 
of malaria.  
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Figure legends 
 
Figure 1. Extraction and detection of Pf NAs from used RDTs. A) Recovery rates of Pf DNA from 
RDTs collected in asymptomatic Tanzanian school children. B) Comparison of extraction perfro-
mance of four protocols based on Cq values of the human rnasep gene. C)  Association of parasite 
densities and Cq values of freshly prepared Pf strains (PfDD2, PfHB3 and PfNF54). Grey colour 
indicates failed detection. D) Correlation between parasite densities of selrial diluted PfIS and Cq 
values for PlasQ targets. Red coloured dots represent samples with failed amplification. 
 
Figure 2. Evaluation of ENAR protocol using samples collected during CHMI studies. A) Pf 
detection rates grouped by parasite density and storage time. B) Quantification ratio between densities 
derived from ENAR and densities derived from whole blood qPCR (WB-qPCR). C) Diagnostic sen-
sitivity of rapid diagnostic test (RDT), ENAR followed by qPCR detection (qPCR) and ENAR fol-
lowed by RT-qPCR detection (RT-qPCR) in relation to parasite density. Rolling means of 10 obser-
vations, using WB-qPCR as a gold standard, are shown with 95% CIs (shaded areas). D) Correlation 
of parasite densities obtained from DNA extracted from fresh whole blood and NA extracted by 
ENAR. 
 
Figure 3. Adaptation of ENAR protocol for analyzing large numbers of barcoded RDTs. A) 
Malaria indicator survey is conducted which includes a detailed questionnaire. B) Malaria prevalence 
is determined by RDT followed by storage of barcode labelled RDTs. C) Sorting and tracking of 
RDTs using smartphone apps. D-F) High throughput protocol for extraction of NA from RDTs using 
the ENAR approach. G) Detection and quantification of Pf and non-Pf malaria parasite. H) Automated 
analysis of qPCR data using ELIMU-Mdx. I) Genotyping of pfk13 propeller region for drug re-
sistance monitoring. 
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Figure 4. Parasite densities among asymptomatic individuals and implication for sequence anal-
ysis. A) Age group dependent parasite densities. B) Association between parasite density and suc-
cessful amplification of pfk13 for sequence analysis.  
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The global market of in vitro diagnostics, 
comprising tools to detect, diagnose or 
monitor diseases, is estimated to be worth 
US$40–45 billion [1]. One of the fastest 
growing areas is the identification of infec-
tious diseases using molecular diagnostics, 
which is becoming an integral part of 
medical practice and public health 
worldwide [2]. Molecular diagnostic tools, 
especially nucleic acid amplification 
techniques, provide faster, more sensitive 
and often more cost-effective diagnoses 
than traditional culture methods for micro-
biological analysis [3]. Quantitative PCR 
(qPCR) is a well-established method for the 
detection, quantification and typing of 
bacteria, viruses, fungi and protozoa in the 
areas of clinical and veterinary diagnostics, 
as well as food safety [4]. Among the biggest 
advantages of qPCR-based diagnosis are 
the universality in designing and developing 
new assays as well as the widespread avail-
ability of the technology. Moreover, qPCR 
also allows quantification and genotyping 
of pathogens. With the rapid spread of qPCR 
into routine diagnostics, standardization and 
validation processes of qPCR assays and 
data had to be addressed [4]. A first step was 
the publication of the MIQE guidelines [5], 
which has led to a certain degree of standard-
ization in the validation process of qPCR 
assays across different laboratories. In order 
to standardize the qPCR data format the 
real-time PCR data markup language 
(RDML) [13], which stores the data in a 
compressed extensible markup language 
file, was designed [6]. RDML stores the raw 
data acquired by the qPCR instrument as 
well as the information required for its inter-
pretation, such as sample annotation and 
cycling protocol. A comprehensive review 
of 27 open-access software packages and 
tools for qPCR data analysis reported that 
most tools use their own file format and only 
a fraction of the currently existing tools 
support the standardized data exchange 
format RDML [7]. The lack of a common 
standard for qPCR data makes it difficult to 
share and analyze data across different 
qPCR platforms.
The high-throughput character of qPCR 
analysis in infectious disease diagnosis 
easily leads to a rapid accumulation of raw 
data that needs to be quality controlled and 
interpreted in order to correctly identify 
and quantify infectious agents. Therefore, 
access to well-designed, user-friendly and 
semi-automated software facilitating the 
storage, quality control (QC) and analysis 
of diagnostic qPCR data is needed.
Controlled human malaria infection 
(CHMI), the deliberate exposure of human 
volunteers to fully infectious malaria 
parasites, has proven to be safe and well 
tolerated, and accelerates the evaluation 
of malaria vaccines candidates in clinical 
trials [8,9]. Volunteers participating in 
CHMIs must be monitored closely to ensure 
volunteer safety. Blood is drawn twice 
daily for up to 2 weeks and screened for 
Plasmodium falciparum parasites by thick 
blood smear microscopy, and after the 
first appearance of blood-stage parasites 
the antimalarial treatment is initiated. 
Nowadays, more sensitive qPCR is increas-
ingly used in CHMI to closely monitor 
parasitemia levels, which improves the 
safety of participants [10]. In order to 
manage the vast amount of qPCR data 
generated during a series of CHMI studies 
with more than 250 individuals included 
and conducted in Tanzania and Equatorial 
Guinea, we decided to design and build a 
platform that facilities the analysis and 
interpretation of diagnostic qPCR data. We 
identified several key features which in our 
opinion would be required for such software:
• Highly adaptable and integrative: a so-
ELIMU-MDx: a web-based, open-source platform 
for storage, management and analysis of diagnostic 
qPCR data
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ABSTRACT
The Electronic Laboratory Infor-
mation and Management Utensil for 
Molecular Diagnostics (ELIMU-MDx) 
is a user-friendly platform designed 
and built to accelerate the turnaround 
time of diagnostic qPCR assays. 
ELIMU-MDx is compliant with the 
MIQE guidelines and has extensive 
data-import capabilities for all major 
qPCR instruments by using the RDML 
data standard. This platform was 
designed as an open-source software 
tool and can be accessed through the 
web browser on all major operating 
systems.
METHOD SUMMARY
ELIMU-MDx is an open-source 
web-application developed using PHP 
to analyze, manage, validate and store 
user-provided qPCR data in a MySQL 
database.
Reports
www.BioTechniques.com2 No. 5 | Vol. 67 | © 2019 Tobias Schindler
lution that can be easily adapted to a 
variety of qPCR assays, supports semi-
automated data analysis and integrates 
into existing sample workflow;
• Data traceability throughout analysis 
process: the use of an audit trail and 
community data standards to ensure 
high data integrity;
• Accessibility and reliability of software: 
Platform-independent, open-source and 
low-maintenance software that could be 
deployed rapidly to new laboratories and 
other projects using qPCR analysis as a 
monitoring tool.
To address these needs, we developed 
the web-based, open-source platform 
ELIMU-MDx (Electronic Laboratory Infor-
mation and Management Utensil for 
Molecular Diagnostics).
MATERIAL & METHODS
ELIMU-MDx development
ELIMU-MDx combines a relational SQL 
database with a user-friendly web interface 
programmed in PHP 7.2 using the framework 
Laravel 5.8 and the tool Laravel Nova 2.0. 
The platform is accessed through a web 
browser (Google Chrome, Firefox and Safari 
were successfully tested) and needs to be 
hosted on a nginx or apache server. It 
validates user-provided data and stores it in 
a MySQL 5.7 database, and where appro-
priate constraints ensure data consistency.
Analysis of qPCR data by ELIMU-MDx
qPCR data generated for diagnostic 
purposes have different requirements to 
software than data generated for other 
qPCR applications. Most importantly, the 
consistency and reliability of the data needs 
to be ensured. Each qPCR run needs to have 
controls in place to test for contamination 
(preventing false-positive results) and to 
test the performance of extraction and 
qPCR reaction (preventing false-negative 
results). All data uploaded to ELIMU-MDx 
is quality controlled based on several 
controls and predefined criteria. Only 
samples that pass all QC thresholds are 
considered for further analysis. Additionally, 
a sample measured multiple times with the 
same assay is automatically considered as 
technical replicates, even if the data are 
derived from different experiments. This 
allows users to repeat sample analysis if 
needed.
ELIMU-MDx processes qPCR data derived 
from both major qPCR detection technol-
ogies. Assays using dye-based (e.g., SYBR or 
Eva-Green dyes) or TaqMan-based detection 
can be analyzed. The quantification cycle 
(Cq) values, the number of cycles needed to 
reach a fluorescence threshold, is extracted 
from the RDML file and used for qualitative 
and quantitative interpretation of the qPCR 
assay. In case of a dye-based detection, 
only Cq values from samples whose 
amplicon has a melting temperature within 
a predefined range are considered for further 
analysis. Since the melting temperatures are 
not included in the RDML version 1.1 from 
Bio-Rad (CA, USA), CFX Maestro (Version 
4.1.2433.1219) and RDML version 1.2 from 
MyGo Pro PCR Software (Version 3.4; IT-IS 
Life Science, Republic of Ireland), they need 
to be uploaded separately in addition to the 
RDML file.
The current version of ELIMU-MDx 
supports absolute quantification of the 
qPCR target molecules using the slope and 
intercept derived from the linear relationship 
between Cq values and serially diluted 
standards of known nucleic acid concen-
trations.
The assay definition file (ADF) includes 
all assay-specific parameters that together 
define the assay. ADF is used by ELIMU-MDx 
for data analysis using different thresholds 
and parameters depending on the actual 
experimental settings. The advantage of 
defining all assay parameters in one single 
file is its universality and easy adaption to 
new qPCR assays. An example for an ADF 
is provided as an excel file (Supplementary 
file 1).
RESULTS & DISCUSSION
ELIMU-MDx overview
The structure of ELIMU-MDx is shown in 
Figure 1. ELIMU-MDx consists of three 
modules – the sample module, the assay 
module and the data module – which are 
connected by an experiment. Each of the 
modules is supplied with data and param-
eters from predefined components. These 
components contain sample-, assay- or 
data-specific information that are necessary 
to interpret and document the experiments. 
The ADF, which contains all parameters 
necessary to analyze samples measured 
with the appropriate qPCR assay, is linked 
through the assay to the experiment. The 
experiment is considered the central node 
of ELIMU-MDx and combines the sample 
and assay metadata with qPCR raw data. 
Upload of standardized data is followed by 
initial QC and automated analysis and 
eventually results in a downloadable result 
file, which can be used for generating reports 
or statistical computing and data visual-
ization by any statistical software. 
Examples of the ELIMU-MDx user 
interface are illustrated in Figure 2. All 
features are accessible through a sidebar 
(Figure 2A). The oligo details are shown 
as an example for the level of detail that is 
provided by ELIMU-MDx’s virtual freezer 
(Figure 2B). As part of the built-in sample 
inventory, the storage position of each 
sample can be displayed (Figure 2C). Results 
are automatically displayed after uploading 
the qPCR RDML files and samples with 
inconclusive results can be easily identified 
using the custom-build filters (Figure 2D). 
The integrated audit trail records all major 
events and therefore ensure high data 
integrity (Figure 2E). 
ELIMU-MDx is built as an open-source 
web-app
ELIMU-MDx is a user-friendly platform 
designed and built to accelerate the 
turnaround time of diagnostic qPCR assays. 
The advantages of web-based applications 
include rapid deployment, cross-platform 
compatibility and easy application devel-
opment [11]. A detailed guide to setup the 
platform, with step-by-step instructions, is 
provided at https://sparclex.github.io/elimu. 
The low-maintenance structure is an 
additional advantage, particularly in 
resource-limited settings. The source code 
is open source and distributed under a MIT 
license and is publicly available for 
download. ELIMU-MDx is unlike most 
commercially available qPCR software in 
that it is not a black box. All features of 
ELIMU-MDx are completely disclosed and 
can be improved or changed by other 
members of the scientific community or 
even used separately in other software.
The ELIMU-MDx can be accessed 
through https://elimu.ch, where we have 
created a specific user account for demon-
stration purposes (login: demo.user@elimu.
ch, password: elimu2019).
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ELIMU-MDx uses the RDML data 
standard, making it qPCR instrument 
independent
ELIMU-MDx supports RDML, a structured 
and universal data standard for exchanging 
qPCR data. RDML files contain all infor-
mation to understand the experimental 
setup, reanalyze the data and interpret the 
results. The use of the RDML data standard 
allows using data from different qPCR instru-
ments. The platform was successfully tested 
with RDML files version 1.1 and 1.2 from the 
Bio-Rad CFX96 Real-Time System and the 
MyGo Pro qPCR instrument.
Semiautomated data QC & analysis 
improves sample-to-result turnaround 
times
The use of the standardized data format of 
RDML files allowed us to automate QC, 
analysis, and validation of qPCR data. Initial 
QC includes the automated analysis of the 
positive, negative and nontemplate control 
of each qPCR run uploaded based on 
provided cut-off values. The internal control 
of each sample is used to validate the 
extraction and amplification performance. 
Based on the Cq values provided by the 
RDML file and a set of assay-specific param-
eters, as defined by the ADF, QC as well as 
qualitative and/or quantitative analysis is 
performed.
The ELIMU-MDx platform was exten-
sively tested with diagnostic qPCR data 
generated during CHMI studies in Tanzania 
(total of 478 samples) and Equatorial 
Guinea (total of 2907 samples). To demon-
strate the advantages and speed of ELIMU-
MDx, we used three separate qPCR runs 
generated during CHMI studies for a head-
to-head comparison with data-management 
solutions based on Microsoft (MS; WA, USA) 
Excel and a previously used custom-built MS 
Access database (Figure 3). At each of the 
four main steps of qPCR data management, 
the use of ELIMU-MDx allows for faster 
processing of qPCR data. With ELIMU-MDx 
the initial QC of the qPCR run is automatically 
performed during the upload of the qPCR 
data and by using a single, standardized 
RDML file containing the qPCR raw data, the 
upload procedure to ELIMU-MDx is simple 
and faster. Once the data are uploaded, the 
Cq values are interpreted and the result 
is linked to the sample. At this step, after 
a manual review of the data, the results 
are summarized and ready to be reported. 
Overall, the entire process from initial QC to a 
final report took approximately 15 min using 
ELIMU-MDx. This is a significant reduction in 
time spent on QC and analysis of the qPCR 
data when compared with the two other data 
analysis tools.
ELIMU-MDX simplifies documentation, 
statistical analysis & visualization of 
qPCR experiments
The combination of assay-specific infor-
mation, as provided by the ADF, sample 
metadata and data provided by the RDML 
file, contains all information required by the 
MIQE guidelines. Table 1 lists all information 
documented for each qPCR experiment as 
defined by the ELIMU-MDx platform.
The ELIMU-MDx platform also serves as 
a laboratory information and management 
system. We added general features of a 
laboratory information and management 
system to the ELIMU-MDx platform. A 
unique storage position can be assigned 
to each sample to keep track of sample 
storage. If samples are shipped, all details 
of the shipment will be logged. Apart from 
qPCR data, all other types of results can 
Modules 
Central node
Components
Samples
Automated quality control, 
analysis and interpretation of data.
Non-qPCR data
Data in xlsx file format
Sample inventory
storage and 
shipment logs
Lab journal
Repository for lab 
protocols and SOPs
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e.g., identifier and 
collection date
Instruments
Repository for instruments 
and maintenance logs
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Parameters for analysis 
and interpretation of data
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programs
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biological type of 
specimen
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qualitative interpretation of 
qPCR data
–  Slope and intercept for 
quantification of qPCR 
result
Documentation parameters
–  Assay-specific values such 
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Figure 1. Structure of ELIMU-MDx. The sample, assay and data modules are connected to create an experiment, which is the central node of the 
platform. Assay-specific parameters are provided through the assay definition file. 
Cq: Quantification cycle; RDML: Real-time PCR data markup language; SOP: Standard operating procedure.
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Figure 2. User interface of ELIMU-MDx. (A) Side bar for navigation within ELIMU-MDx. (B) Oligo details as an example for an ELIMU-MDx component. 
(C) Automatically assigned storage position for samples. (D) Samples that need special attention can be filtered in the results section. (E) ELIMU-MDx 
audit trail. Cq: Quantification cycle; SOP: Standard operating procedure.
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be uploaded and attached to the samples, 
and therefore linked with the qPCR result. 
Importantly, the structured data generated 
by ELIMU-MDx allows use of the R language 
and environment for statistical computing 
and visualization of qPCR data without 
extensive data cleansing.
Integrity & traceability of qPCR data in 
ELIMU-MDx
All qPCR data uploaded to ELIMU-MDx are 
protected from accidental or intentional 
modifications. The original qPCR raw data, 
as a RDML file, are attached to the results. 
The Cq values cannot be changed or deleted; 
the only option is to exclude replicates. 
Exclusion of Cq values is visually indicated 
and can be reversed. Each modification of 
the data is attributed to a user. The use of 
personal accounts that are password 
protected and the automatic creation of an 
audit trail that records and logs all major 
changes are in line with US FDA regulations 
on electronic records and electronic signa-
tures (FDA regulation 21 CFR Part 11).
qPCR is a powerful tool that is used 
in different areas of infectious disease 
diagnostics, and it has become a key 
technology for the detection of viruses, 
bacteria, fungi and parasites by increas-
ingly replacing traditional diagnostic 
techniques [4]. For laboratories, especially 
if they generate diagnostic data for clinical 
trials, the adequate storage, curation and 
analysis of qPCR data can be a challenge. 
Currently available software solutions, 
commercial or open source, are not well 
suited for the management and analysis of 
diagnostic qPCR data. Often a combination 
of several tools is used with an inadequate 
documentation of this essential step of the 
qPCR workflow.
We have built the ELIMU-MDx platform as 
a response to the large amount of qPCR data 
generated during clinical trials, including 
CHMI studies. Due to its integration into 
the sample workflow and automation of 
the qPCR QC and preliminary analysis, the 
use of ELIMU-MDx accelerates the sample-
to-result turnaround time significantly. The 
use of the RDML standard allows analysis of 
the qPCR data in a streamlined and trans-
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Figure 3. Analysis of qPCR data using ELIMU-MDx. Time spent on different steps of qPCR data 
management compared between Microsoft Excel, a custom-built Microsoft Access database and 
ELIMU-MDx. 
QC: Quality control.
Table 1. Information documented for each experiment and sample.
Modules Component Description
Sample module Sample metadata Required is a unique identifier, collection date and biological type of sample. 
 Optional information such as demographics can be added
 Sample inventory Contains information related to storage and shipment of samples
Assay module Lab journal Contains detailed information for the associated protocols and standard operating 
procedures 
 Instruments A detailed repository for qPCR instruments, which also includes maintenance logs
 Virtual freezer Contains information for:  
Oligonucleotides: sequences, link to original publication 
Reagents: qPCR reagents with lot number and expiry date and extraction kits for 
nucleic acids 
Controls: name and concentration of positive controls 
qPCR programs: Cycling conditions and detection channels used. qPCR instrument 
software name and version
Data module qPCR raw data Quantification cycle values and melting temperatures provided by RDML file
 qPCR metadata Metadata for each run are saved within the RDML file
Assay definition 
file
Analysis parameters Assay-specific parameters that are used to analyze and interpret the qPCR data. For 
details, refer to the ELIMU-MDx user guide
 Documentation parameters Additional assay-specific parameters, e.g., qPCR efficiencies, which are used for 
documentation purposes only
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parent way without losing the association 
between the final result (interpretation of 
the qPCR data) and the raw data (fluorescent 
data of the qPCR run). We also placed impor-
tance on the documentation of the qPCR 
experiments by attaching metadata from 
the samples and assays to the qPCR data. 
Maintaining an audit trail is a regulatory 
compliance requirement; therefore, we 
integrated an automated, time-stamped 
audit trail that allows the reconstruction 
of all events related to the creation, modifi-
cation or deletion of electronic records.
ELIMU-MDx is open source, licensed 
under the permissive MIT license. 
Disclosing the software code used for 
data analysis should be the standard and 
will help to increase the reproducibility of 
data analysis [12]. Because ELIMU-MDx is 
an open-source project, contributions and 
feedback from the community are highly 
encouraged and will be an important factor 
in improving and adaptation of ELIMU-MDx 
over time.
FUTURE PERSPECTIVE
With the rapid spread of qPCR-based 
technologies for infectious disease 
diagnostics, the development and imple-
mentation of software for qPCR data 
analysis will continue to gain importance, 
particularly in the framework of clinical inter-
vention studies that need to follow good 
laboratory practices. Open access software 
tools that enable reproducible data analysis, 
audit trails and long-term storage of raw and 
analyzed qPCR data are likely to become 
essential in experimental clinical research 
and diagnostics in the foreseeable future.
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A multiplex qpcR approach for 
detection of pfhrp2 and pfhrp3 
gene deletions in multiple 
strain infections of Plasmodium 
falciparum
tobias Schindler  1,2, Anna C. Deal1,2, Martina fink1,2, Etienne Guirou  1,2, Kara A. Moser3, 
Solomon M. Mwakasungula4, Michael G. Mihayo4, Said A. Jongo4, Prosper P. chaki4, 
Salim Abdulla4, Paulo C. Manrique Valverde5, Katherine torres5, Jose R. Bijeri6, Joana C. Silva  5, 
Stephen L. Hoffman7, Dionicia Gamboa5, Marcel tanner1,2 & claudia Daubenberger1,2
the rapid and accurate diagnosis of Plasmodium falciparum malaria infection is an essential factor in 
malaria control. Currently, malaria diagnosis in the field depends heavily on using rapid diagnostic tests 
(RDTs) many of which detect circulating parasite-derived histidine-rich protein 2 antigen (PfHRP2) in 
capillary blood. P. falciparum strains lacking PfHRP2, due to pfhrp2 gene deletions, are an emerging 
threat to malaria control programs. The novel assay described here, named qHRP2/3-del, is well suited 
for high-throughput screening of P. falciparum isolates to identify these gene deletions. The qHRP2/3-
del assay identified pfhrp2 and pfhrp3 deletion status correctly in 93.4% of samples with parasitemia 
levels higher than 5 parasites/µL when compared to nested PCR. The qHRP2/3-del assay can correctly 
identify pfhrp2 and pfhrp3 gene deletions in multiple strain co-infections, particularly prevalent in Sub-
Saharan countries. Deployment of this qHRP2/3-del assay will provide rapid insight into the prevalence 
and potential spread of P. falciparum isolates that escape surveillance by RDTs.
Malaria is an infectious disease with an estimated 219 million cases globally and was responsible for 435’000 
deaths in 2017. More than 90% of these malaria cases and deaths occurred in sub-Saharan Africa with 
Plasmodium falciparum as the most pathogenic malaria parasite species, accounting for the vast majority of clin-
ical malaria cases1.
Advances have been made in malaria control which have contributed to the decline in malaria prevalence 
observed worldwide with improved diagnostic tests and better access to malaria treatment contributing signif-
icantly to this development1. The rapid and accurate diagnosis and treatment of malaria cases is an essential 
factor in the control of malaria. Rapid diagnostic tests (RDTs) are becoming the most widely used method to 
diagnose malaria infections in the field with 245 million RDTs distributed worldwide in 20171. In sub-Saharan 
Africa an estimated 75% of malaria tests conducted in 2017 were based on RDTs1. Malaria RDTs are based on 
an immuno-chromatographic assay using a lateral-flow device which allows the detection of malaria antigens in 
usually 5 to 15 µL of capillary blood2. RDTs provide results within 20 minutes and can be employed by inexperi-
enced health workers operating in resource-limited settings3. RDTs recognizing circulating histidine-rich protein 
2 (PfHRP2) for sensitive and specific detection of P. falciparum make up more than 90% of RDTs currently in 
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use4. The relatively high abundance and stability of PfHRP2 in the blood of infected patients and expression by P. 
falciparum during the erythrocytic stage makes this antigen a valuable biomarker for malaria infection5. PfHRP3, 
a protein also expressed by P. falciparum with high level of structural similarity to PfHRP2, might be also recog-
nized by some of the monoclonal antibodies used in the RDTs6. RDTs are critical diagnostic tools for identifying 
symptomatic malaria infections; however, due to the reduced performance in infections with low parasite density, 
its use for the diagnosis of malaria infection in asymptomatic individuals is rather limited7.
Recent studies report on reduced diagnostic performance of PfHRP2-based RDTs which were attributed 
to genetic diversity of the pfhrp2/3 genes6, differences in expression level of PfHRP2/3 antigen in parasite field 
strains8 or isolates lacking pfhrp2 and/or pfhrp3 genes9. P. falciparum isolates lacking pfhrp2 and/or pfhrp3 genes 
are found around the world, with different proportions of the circulating P. falciparum population affected. The 
regions with the highest proportions of P. falciparum strains carrying pfhrp2 deletions are South America and 
sub-Saharan Africa10. Since malaria control programmes depend on reliable diagnosis of malaria cases using 
RDTs, parasites lacking pfhrp2/3 genes pose a threat to malaria control and local elimination efforts11.
The presence or absence of pfhrp2/3 genes is usually determined by amplifying these genes by polymerase 
chain reaction (PCR). Several different (nested) PCR protocols have been published and a deletion is reported if 
there is no amplification of the pfhrp2/3 genes in the presence of an amplification in at least two P. falciparum sin-
gle copy genes12. The conventional nested PCR methods are time consuming, requiring separate reactions for each 
target gene amplification as well as gel electrophoresis for visualization of the PCR products. Additionally, there 
are methodological issues related to this approach which assumes identical PCR performance of the pfhrp2/3 and 
the reference genes. Particularly at lower parasitemia levels with a small number of DNA target molecules pres-
ent, unavoidable stochastic effects can play a major role and might lead to false reporting of pfhrp2/3 deletions. 
Furthermore, none of the published methods detecting pfhrp2/3 deletions can identify “masked” deletions in 
multiple strain infections with only one out of several P. falciparum strains carrying a pfhrp2 and/or pfhrp3 gene 
deletion13. These limitations of recommended molecular monitoring methods could result in an underestimation 
of the prevalence of P. falciparum strains with pfhrp2/3 deletions, especially in regions with high proportions of 
multiple strain co-infections.
This paper presents a novel, quantitative PCR-based method for detecting pfhrp2 and pfhrp3 gene deletions 
suitable for high throughput screening of P. falciparum isolates. The qHRP2/3-del (quantitative detection of 
pfhrp2 and pfhrp3 deletion) assay was developed as a multiplex assay, with the ability to amplify individually and 
specifically the pfhrp2 and pfhrp3 genes together with a single copy gene, the P. falciparum ribonucleotide reduc-
tase R2_e2 (pfrnr2e2)14, as an internal reference. The quantitative nature of the qHRP2/3-del assay provides the 
basis for estimating the proportions of P. falciparum strains carrying pfhrp2 and pfhrp3 deletions in regions with 
multi-clonal malaria infections.
Results
Design and evaluation of the novel qHRP2/3-del assay. We aimed at improving the detection of 
pfhrp2 and pfhrp3 gene deletions by developing a quantitative PCR-based assay able to detect and quantify pfhrp2 
and pfhrp3 genes in a single reaction. Given the high nucleotide sequence similarity and the repetitive struc-
ture of the pfhrp2 and pfhrp3 genes, nucleotide regions serving as targets for primers and probes were limited 
(Supplementary File 1). The primer and probe combinations selected for our assay (Table 1) bind to a region 
spanning exon 1 and exon 2 of both genes. Absence of amplification will therefore indicate a deletion of the entire 
genes or partial gene deletions including exon 1, the intron and first 96 base pairs of exon 2. Although there are 
chromosome breaking points outside the amplified regions, in particular the section that contains the repeats 
and epitopes detected by RDTs, analysis of field isolates suggest that the selected regions are highly predictive for 
pfhrp2/3 deletions in field strains9,12,15,16.
We designed a multiplex qPCR assay using three differently labelled TaqMan assays detecting the pfhrp2 
(PF3D7_0831800) and pfhrp3 (PF3D7_1372200) genes with the single copy gene pfrnr2e2 (PF3D7_1015800) 
as the internal control. The sequence alignment of the pfhrp2 and pfhrp3 genes highlighting the oligo binding 
regions is shown in Supplementary File 1.
The multiplexed assays correctly identify P. falciparum strains carrying known deletions of pfhrp2 (PfDD2 
strain) and pfhrp3 (PfHB3 strain) as well as a strain without deletion (PfNF54 strain) (Fig. 1A). The multiplexed 
assays show comparable characteristics in terms of sensitivity and qPCR performance. Using DNA extracted from 
Target gene Size Oligo name Oligo sequence [5′ to 3′] Fluorophores Conc. in 5 × PrimerMixa
pfrnr2e2
(PF3D7_1015800) 107 bp
IC-PfRNR2E2 fwd AGTATCCAAAACACTATAATTCCAAGTAC — 1.5 µM
IC- PfRNR2E2 rev ATTTTCTCCTTTCTTAACAGTTTCTTCC — 1.5 µM
IC-PfRNR2E2 Cy5 CCTTTTAGTTGGCCCGAATTTACAA Cy5-BHQ2 1.125 µM
pfhrp2
(PF3D7_0831800) 286 bp
PfHRP2 fwdb GTATTATCCGCTGCCGTTTTTGCC — 1.5 µM
PfHRP2 revb TCTACATGTGCTTGAGTTTCG — 1.5 µM
PfHRP2 TxRd TTCCGCATTTAATAATAACTTGTGTAGC TexasRed-BHQ2 0.375 µM
pfhrp3
(PF3D7_1372200) 289 bp
PfHRP3 fwd ATATTATCCGCTGCCGTTTTTGCT — 1.5 µM
PfHRP3 rev CCTGCATGTGCTTGACTTTCGT — 1.5 µM
PfHRP3 YY CTCCGAATTTAACAATAACTTGTTTAGC YakimaYellow-BHQ2 0.75 µM
Table 1. Oligonucleotide sequences used for qHRP2/3-del assay. aAll oligonucleotides are premixed as a 5× 
primer mix. bOligonucleotide sequences obtained from Abdallah et al.32.
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cultured parasites, all three targets are detected in samples with parasitemia as low as 1 parasite/µL and an inverse 
linear correlation between Cq values and parasite densities ranging from 1 to 10’000 parasites/µL was observed. 
The qPCR efficiencies were calculated as 85.7%, 98.8% and 98.4% for the amplification of pfhrp2, pfhrp3 and 
pfrnr2e2, respectively (Fig. 1B). The qHRP2/3-del assay was next tested using purified DNA from eight culture 
adapted P. falciparum strains from Africa (Pf3D7, PfNF54, PfNF166.C8), South and Central America (Pf7G8, 
PfHB3), South East Asia (PfNF135.C10, PfDD2) and Papua New Guinea (PfFC27) with known deletion status 
of the pfhrp2 and pfhrp3 genes. The Cq values for amplification of pfrnr2e2 were comparable between the eight 
strains amplified and no significant differences of Cq values for the pfhrp2 gene and pfhrp3 gene across the strains 
carrying the genes was observed. Sequence alignments of PfNF135.C10, Pf3D7, Pf7G8, PfNF54 and PfNF166.
C8 did not reveal sequence variation in the oligo binding regions of pfhrp2 (Supplementary File 2) or pfhrp3 
(Supplementary File 3) supporting these findings. DNA derived from five non-falciparum Plasmodium species (P. 
ovale curtisi, P. ovale wallikeri, P. malariae, P. knowlesi, P. vivax) was tested with the qHRP2/3-del assay and did 
not result in amplification of any target demonstrating the specificity for P. falciparum. In summary, we developed 
a P. falciparum-specific multiplex qPCR assay that allowed the simultaneous amplification of the pfhrp2, pfhrp3 
and pfrnr2e2 genes in a single reaction with high efficiency and ability to correctly identify pfhrp2 and pfhrp3 
gene deletions.
Figure 1. Multiplex detection of pfhrp2 and pfhrp3 genes using the qHRP2/3-del assay. (A) The qHRP2/3-
del assay amplifies pfhrp2, pfhrp3 and pfrnr2e2 target sequences in a multiplex qPCR reaction and correctly 
identifies strains carrying either a pfhrp2 deletion (PfDD2), a pfhrp3 deletion (PfHB3) or no deletion (PfNF54). 
(B) Performance characteristic of each individual amplification assay, run within the multiplex qHRP2/3-del 
assay, is shown. Correlation with high linearity between serially diluted WHO international standard for P. 
falciparum NATs (PfIS) and Cq values was obtained and used to calculate the qPCR efficiency. Cq values above 
40 (black line) are considered negative.
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Analysis of P. falciparum field strains with qHRP2/3-del assay. The qHRP2/3-del assay was next 
tested using a collection of 254 P. falciparum isolates originating from East Africa, Central-West Africa and 
Latin America (Table 2). The infection status and parasitemia levels were well established in these samples by 
using published diagnostic qPCR assays routinely used in the laboratories in Tanzania17, Equatorial Guinea18 
and Peru19. The overall median parasitemia in these samples was 75.7 parasites/µL (IQR: 2.2–571.6), which is 
below the LOD of 100 parasites/µL for PfHRP2-based RDTs20,21. First, the ability of the pfrnr2e2 singly copy 
gene to serve as internal assay control and to quantify parasitemia levels was assessed. Out of the 254 samples, 
186 (73.2%) amplified the pfrnr2e2 singly copy gene. Failure in amplification of pfrnr2e2 was associated with low 
parasitemia levels (Fig. 2A). In samples with parasitemia levels of 3 parasites/µL and above, more than 95% of all 
samples were amplified successfully. In samples with parasitemia >100 parasites/µL, the lower limit of detection 
for PfHRP2-based RDTs, all qPCR reactions were positive for pfrnr2e2. Parasitemia levels determined by using 
the amplification of pfrnr2e2 correlated closely with parasite densities obtained from P. falciparum diagnostic 
qPCR assays (Fig. 2B), this is supported by the findings of the Bland-Altman plot which demonstrates a high 
order of agreement (Fig. 2C). The average ratio of parasite quantification based on diagnostic qPCR assays and 
qHRP2/3-del assay is 0.8 (95% CI: −1.7–3.3). In summary, the qHRP2/3-del assay amplifies 95% of samples with 
parasitemia levels of 3 parasites/µL and above and can be used to reliably quantify parasite levels in field samples.
Identification of pfhrp2 and pfhrp3 gene deletions using qHRP2/3-del assay. Next, we wanted 
to establish the performance of the qHRP2/3-del assay in comparison with nested PCR. Samples with known 
pfhrp2/3 deletion status obtained from four different sources were included. Serial dilutions of DNA purified from 
PfDD2 (pfhrp2 deletion), PfHB3 (pfhrp3 deletion) and PfIS (no deletion) served as controls. Samples from CHMI 
using PfNF54 (no deletion) were added to test the specificity of the qHRP2/3-del assay. Two sample sets geno-
typed by nested PCR, one from Tanzania (TZ) dominated by P. falciparum strains without deletions and one from 
Peru (PE), with a high proportion of pfhrp2/3 deletions were analysed. The Peruvian sample set consisted of 54 
samples with both genes deleted and 7 samples with only one gene deleted. The qHRP2/3-del assay defines a dele-
tion as failure of amplification of the pfhrp2/3 genes (Fig. 3A, y axis, Cq set to 45) in samples which are positive 
for the internal control, pfrnr2e2 (Fig. 3A, x axis). Sensitivity is defined as the proportion of correctly identified 
pfhrp2/3 deletions, while specificity is the proportion of correctly identified strains without pfhrp2/3 deletions. 
All control samples with known deletion status were identified as expected (Fig. 3A, first panel). Importantly, 
the qHRP2/3-del assay correctly identified samples with parasitemia levels ranging from 1–10’0000 parasites/
µL, demonstrating the dynamic range of at least 5 logs of this assay. In samples collected from volunteers that 
have undergone CHMI with PfNF54 (CHMI, n = 38), one sample that is positive for pfhrp2/3 genes was wrongly 
detected as a double deleted parasite, resulting in a reduced specificity (Fig. 3A, second panel). A high sensitivity 
was achieved with the Peruvian samples (PE, n = 67), pfhrp2 and pfhrp3 deletions were detected with sensitivity 
of 94.4% and 94.9%, respectively (Fig. 3A, third panel). The low specificity of 76.9% and 87.5% for pfhrp2 and 
pfhrp3, respectively, is based on the incorrect detection of deletions in three samples. Among the samples from 
Tanzania (TZ, n = 56), no pfhrp2/3 deletions were detected by the nested PCR. In contrast, the qHRP2/3-del assay 
identified three deletions, resulting in a specificity of 93.8% (Fig. 3A, fourth panel).
Grouping the samples with missed deletions (reducing the sensitivity) and the false deletions (reducing the 
specificity) by parasitemia levels revealed a high proportion of false deletions among the samples with the low-
est parasitemia levels (Fig. 3B). Based on these findings, the inclusion criteria for samples to be analysed by 
qHRP2/3-del assay was changed. The threshold for the pfrnr2e2 gene amplification was reduced from Cq < 40 
to Cq < 37.5, corresponding to parasitemia levels of 5 parasites/µL. Based on these new inclusion criteria, the 
qHRP2/3-del assay obtained results from 106 samples out of 127 samples (inclusion rate of 83.5%) (Fig. 3C). 12 
samples were not amplified by the qHRP2/3-del assay and an additional 9 samples excluded based on the new 
inclusion criteria. Samples which were not amplified by the qHRP2/3-del assay were mainly ultra-low parasite 
density samples from Tanzania (11 out of 12).
In 99 out of 106 samples (93.4%), the pfhrp2/3 deletion status was identical when compared between 
qHRP2/3-del assay and nested PCR. This is reflected in the near perfect agreement between these two PCR based 
diagnostic methods for each of the amplified targets. Cohen’s kappa was calculated as 0.89 and 0.91 for pfhrp2 
and pfhrp3, respectively. Out of the seven samples which were misidentified in four samples both pfhrp genes 
were affected, while in two samples the pfhrp2 and in one sample the pfhrp3 status was misclassified. For four 
misidentified samples with higher parasitemia levels the possibility of sample mix-up or cross-contamination 
Sample set Description of sample set
Number of P. falciparum 
positive samplesb
Parasitemia in parasites/
µL (Median/IQR)
Amplification rate by 
qHRP2/3-del assayc
CHMIa CHMI in TZ with PfNF54 strain (no deletion) 49 51.1 (1.5–152.5) 78%
PE Peruvian samples around Iquitos city. High proportion of pfhrp2/3 deletions 68 592.4 (186.7–1982.0) 99%
EG Blood donors with asymptomatic malaria infection living on Bioko Island, Equatorial Guinea 47 4.8 (1.0–45.3) 51%
TZ Sampling of symptomatic volunteers at two health facilities in Southern Tanzania 90 38.8 (0.7–808.6) 62%
Combined 254 75.7 (2.2–571.6) 73%
Table 2. Field samples used for evaluation of qHRP2/3-del assay. aControlled Human Malaria Infection. bAll 
confirmed by diagnostic qPCR assays. cPositive for internal control of assay (pfrnr2e2).
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cannot be excluded, since these samples were located next to each other on the DNA plate which was shipped. In 
summary, the qHRP2/3-del assay specificity (94.4% and 96.0% for pfhrp2 and pfhrp3, respectively) and sensitivity 
(94.2% and 94.6% for pfhrp2 and pfhrp3, respectively) were above 90%. The negative predictive value (NPV) was 
calculated as 94.5% and 94.1% and the positive predictive value (PPV) as 94.2% and 96.4%, for pfhrp2 and pfhrp3, 
respectively (Fig. 3D).
Multiple strain P. falciparum infections are masking pfhrp2 and pfhrp3 deletions. In many 
malaria endemic regions, particularly in sub-Saharan Africa, infections with multiple strains of P. falciparum are 
common22. A blood sample carrying multiple P. falciparum strains with and without pfhrp2/3 deletions will result 
in failure to detect the deletion by nested PCR if the parasitemia level of the strain without deletion is sufficiently 
high for amplification. This limitation leads most likely to an underestimation of the prevalence of pfhrp2/3 gene 
deletions in regions with high prevalence of multiple strain infections. We reasoned that the qHRP2/3-del assay 
could offer a solution by calculating the difference between the Cq values obtained for amplification of pfhrp2 
or pfhrp3 and pfrnr2e2. To demonstrate the ability of the qHRP2/3-del assay to correctly identify and quantify 
Figure 2. Detection and quantification of field samples using qHRP2/3-del assay. (A) Amplification rate of 
pfrnr2e2 target, the internal control of qHRP2/3-del assay and association with parasitemia levels. Wilcoxon-
Mann-Whitney test was used for comparison of parasitemia between groups. The dashed line at 3 parasites/µL  
represents the parasitemia at which more than 95% of the samples were amplified, while the dashed line at 100 
parasites/µL represents the LOD of RDTs at which all samples are successfully amplified. (B) Correlation of 
parasitemia levels, obtained from diagnostic qPCR assays, and parasitemia, derived from the internal control 
of qHRP2/3-del assay, is shown. The color represents the different sample sets and R2 the Spearman’s rank 
correlation coefficient. (C) Bland-Altman plot of average parasitemia (x-axis) and ratio of parasitemia levels 
calculated between internal control of qHRP2/3-del assay and diagnostic qPCR assays (y-axis). Average ratio 
(black line) and 95% limits of agreement (dashed line) are depicted.
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“hidden” or “masked” pfhrp2/3 gene deletions in mixed infections, we first tested defined mixtures of DNA from 
PfNF54 (no pfhrp2/3 deletions) and PfDD2 (pfhrp2 deletion) or PfHB3 (pfhrp3 deletion) in a range of different 
ratios. For each combination of strain mixtures, PfDD2/PfNF54 or PfHB3/PfNF54, 10 mixtures were prepared 
containing varying ratios of strains with and without a pfhrp2/3 deletion (Fig. 4A). The contribution from PfDD2 
and PfHB3 strains to these mixtures ranged from 0.1% to 88% and 0.1% to 86%, respectively. In seven mixtures, the 
strain with a deletion constituted the minority (with less than 50% abundance) and in three mixtures the majority 
(with more than 50% abundance). None of these mixtures failed to amplify the pfhrp2/3 genes, even if the strain 
carrying the deletion constituted the majority in the mixture. A positive correlation between abundance of isolate 
carrying a deletion and an increase of ΔCq (Cq of pfhrp2 or pfhrp3 minus Cq of pfrnr2e2) is observed (Fig. 4B). 
The qHRP2/3-del assay does not only successfully identify “masked” pfhrp2/3 deletions but can also discriminates 
between mixtures where the strain with the deletion constitutes the majority or minority (Fig. 4C). A ΔCq cut-off 
value of 2.0 was chosen to identify “masked” pfhrp gene deletions. Applying this cut-off to our sample collections 
revealed that two isolates each from Tanzania and Peru have high ΔCq values for both pfhrp genes indicative of 
the presence of “masked” pfhrp2/3 deletions (Fig. 4D). Three additional samples from the Peruvian collection had 
a ΔCq value > 2 for the pfhrp2 gene only. No ΔCq values above 2 were found in Equatorial Guinean isolates and 
among samples collected from volunteers undergoing CHMI (Fig. 4D). These experiments demonstrate that by 
calculating the ΔCq values between Cq for pfrnr2e2 and pfhrp2 or pfhrp3, “masked” deletions can be identified.
Discussion
P. falciparum strains carrying pfhrp2/3 deletions are an emerging threat to malaria control and elimination pro-
grams around the world. Novel analysis tools enabling high-throughput screening of P. falciparum populations 
from the field are needed. The currently published methods, mostly based on nested PCR, have clear limitations 
in that these methods are extremely time consuming, prone to detection of incorrect deletions at low parasitemia 
levels and unable to identify “masked” deletions in multiple strain co-infections.
Figure 3. Diagnostic performance of qHRP2/3-del assay. (A) Samples with Cq values for pfhrp2 and pfhrp3 
amplification >40 (shown on y-axis, black line indicates cut-off) are considered to carry a pfhrp2/3 deletion. 
Reference deletion status, based on nested PCR, is color coded (red = deletion, grey = no deletion). (B) 
Proportion of correctly and incorrectly identified pfhrp2/3 deletion status grouped by parasitemia. (C) Number 
of samples included for analysis by qHRP2/3-del assay (n = 106), excluded due to ultra-low parasitemia (n = 9) 
and not amplified (n = 12). (D) Analytical validation of qHRP2/3-del assay performance was assessed by 
comparing it to nested PCR. Standard parameters such as sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) including their 95% confidence intervals are shown.
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The sensitivity and specificity of the PfHRP2/3-del assay is comparable to the widely used nested PCR. 
However, the novel qHRP2/3-del assay is well suited for high throughput screening of P. falciparum isolates with 
approximately 30 samples analyzed in less than two hours - including DNA extraction and data analysis. Two 
additional major advantages of the qHRP2/3-del assay are obvious: firstly, the ability to quantify parasitemia lev-
els and therefore include samples based on parasitemia and secondly, to identify “masked” deletions in multiple 
strain infections.
The identification of pfhrp2/3 deletions in samples with low parasitemia levels is difficult since the absence of 
amplification could be due to lack of sufficient template leading to incorrect reports of deletions. The conventional 
method depends on the successful amplification of at least two single copy reference genes to ensure sufficient 
template in the PCR reaction. This procedure is time-consuming and labour-intensive. The qHRP2/3-del assay 
uses an alternative inclusion criterion, based on the Cq value of its internal control. The pre-defined exclusion 
criteria of all samples that have parasitemia below 5 parasites/µL will improve the quality, reproducibility and 
comparability of malaria parasite survey data obtained with the qHRP2/3-del assay.
The ability to detect “masked” pfhrp2/3 deletions is probably the most interesting feature of the qHRP2/3-del 
assay, because it will allow studying the epidemiology of pfhrp2/3 deletions in malaria endemic regions with a high 
proportion of infections caused by multiplicity of infections, particular sub-Saharan Africa22. The qHRP2/3-del 
assay correctly identified infections that contain two strains, one with a deletion and the other one without a dele-
tion, based on a difference in the Cq values derived from the amplification of the pfhrp2/3 gene targets and the 
pfrnr2e2 control. However, currently we cannot exclude that nucleotide sequence variations located in the bind-
ing sites of the oligonucleotides used in the PfHRP2/3-del assay could potentially also lead to variation in ΔCq 
values. The ΔCq application of our novel PfHRP2/3-del assay in additional studies including a larger sample size 
will improve our understanding of the relevance of “masked” pfhrp2 and pfhrp3 gene deletions and their impact 
on reliability of malaria RDT test results.
Two Tanzanian isolates had an increased ΔCq value for both pfhrp genes, indicating the presence of pfhrp2/3 
deletions in the East African nation. This was recently confirmed when pfhrp2 and pfhrp3 deletions were 
Figure 4. Identification of masked pfhrp2/3 deletions in multiple strain infections. (A) Mixtures containing 
two strains, one with a pfhrp deletion (PfDD2 or PfHB3) and no deletion (PfNF54), were generated. (B) 
Correlation between abundance of strain carrying deletion and ΔCq is shown for both targets, pfhrp2 (red) and 
pfhrp3 (blue). (C) The ΔCq approach distinguishes between strain mixtures not carrying deletions, mixtures 
with minority abundance as well as majority abundance of strains with deletions. Statistical comparison was 
performed using the Kruskal-Wallis test followed by Wilcoxon-Mann-Whitney for pairwise comparisons. 
(D) The ΔCq approach of the qHRP2/3-del assay was applied to four sample collections to identify “masked” 
pfhrp2/3 deletions. The control group, based on samples from CHMI, did not reveal isolates with increased 
ΔCq values. The dashed lines represent the ΔCq cut-off values for pfhrp2 (x-axis) and pfhrp3 (y-axis).
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identified in Tanzania and Uganda23.Together with findings from Kenya24, the Democratic Republic of Congo25, 
Rwanda26 and Mozambique27 there is strong evidence for the existence of pfhrp2/3 deletions in this region. 
Therefore, establishing programs which systematically monitor pfhrp2/3 deletions and their impact on the per-
formance of RDTs is advised.
conclusion
The qHRP2/3-del assay presented here is suitable for high-throughput screening of P. falciparum strains to iden-
tify pfhrp2/3 gene deletions in different malaria endemic settings, including areas with high a proportion of mul-
tiple strain co-infections. With growing availability of qPCR instruments in reference laboratories in sub-Saharan 
countries, this assay could be used as surveillance method to monitor over time the potential expansion of P. 
falciparum strains carrying pfhrp2 and pfhrp3 deletions.
Methods
P. falciparum isolates from tanzania, equatorial guinea and peru. In this study a total of 205 
P. falciparum isolates collected from three different malaria endemic regions, East Africa, West-Central Africa and 
South America were included. The samples from East Africa (n = 90) were collected in rural southern Tanzania 
(TZ) as part of a malaria baseline survey28. The West-Central African isolates (n = 47) were identified among blood 
donors living in Malabo, Equatorial-Guinea (EG)18. Both samples sets were analyzed locally, at the Bagamoyo branch 
of the Ifakara Health Institute and the laboratory of the Equatorial Guinea Malaria Vaccine Initiative using harmo-
nized protocols. Briefly, genomic DNA was isolated either from 6 circles with 2 mm diameter of dried blood spots 
(Tanzania) or 180 µL whole blood (Equatorial Guinea) using the Quick-DNA Miniprep kits (Zymo Research, Irvine, 
USA). P. falciparum was identified and quantified using published qPCR protocols based on varATS29. Extracted 
DNA (n = 68) from Peruvian isolates (PE), collected between 2008–2009 and 2015–2016 around Iquitos city, was 
shipped to the Swiss Tropical and Public Health Institute for pfhrp2/3 characterization by qHRP2/3-del assay.
Additional parasite isolates and laboratory strains. Forty-nine PfNF54 isolates from Controlled 
Human Malaria Infections (CHMI) conducted in Bagamoyo, Tanzania (ClinicalTrials.gov: NCT0261352030) 
as well as genomic DNA isolated from 8 laboratory strains with known pfhrp2/3 deletion status (Pf3D7, 
Pf7G8, PfDD2, PfHB3, PfNF135.C10, PfNF166.C8, PfNF54 and PfFC27) were used as controls. The 1st WHO 
International Standard for Plasmodium falciparum DNA Nucleic Acid Amplification Techniques (NIBSC code: 
04/176, herein referred to as PfIS) was used to assess the performance of the qHRP2/3-del assay. Non-falciparum 
Plasmodium species, including P. malariae (Pm), P. ovale curtisi (Poc), P. ovale wallikeri (Pow), P. vivax (Pv) and 
P. knowelsi (Pk) and an additional 28 samples from malaria negative individuals living in Tanzania were used to 
assess specificity of the assay.
Detection of the pfhrp2 and pfhrp3 genes by conventional nested PCR. P. falciparum positive 
samples collected in Tanzania were selected for detection of pfhrp2 and pfhrp3 genes by nested PCR. As a ref-
erence gene, the msp2 gene was amplified using a previously described protocol31. All isolates with successful 
msp2 amplification were analyzed for the presence of pfhrp2 and pfhrp3 genes using primers spanning exon 1, 
the intron, and exon 232. All PCR products were separated and visualized on a 2% agarose gel. Cultured parasite 
isolate PfDD2 (pfhrp2 deletion) was used as a control for all nested PCR experiments on pfhrp2 while PfHB3 
(pfhrp3 deletion) was used as a control for all nested PCR experiments on pfhrp3. PfNF54 (no pfhrp2/3 deletion) 
was used as a positive control for both pfhrp genes. Pfhrp2/3 deletion status of the Peruvian P. falciparum isolates 
was analyzed previously following the procedures described elsewhere9. Results were shared to be used for the 
evaluation of the qHRP2/3-del assay.
Design of qHRP2/3-del assay. Published pfhrp2/3 primer sequences for conventional PCR were adapted 
to the qPCR platform using EvaGreen® qPCR Mix (Solis BioDyne, Tartu, Estonia). The primers were tested with 
different DNA concentrations extracted from PfNF54, PfDD2 and PfHB3 strains, corresponding to parasitemia 
levels of 1 and 100 parasites/µL. The best performing primer pairs, in terms of specificity and sensitivity, were 
then used in combination with newly designed TaqMan® hydrolysis probes. The pfhrp2/3 oligo sequences were 
systematically optimized using the trial-and-error approach. As the internal control of the qHRP2/3-del assay we 
amplify a P. falciparum specific 107 bp long sequence of the ribonucleotide reductase R2_e2 (pfrnr2e2), a distantly 
related paralog of the canonical eukaryotic small subunit ribonucleotide reductase R2, that is unique to apicom-
plexan species14. The performance of pfrnr2e2 as a biomarker for detection and quantification of P. falciparum 
was tested by direct comparison with parasitemia levels obtained from a 18 S rDNA based qPCR assay33. A sensi-
tivity of 89.1% for samples with parasitemia >1 parasite/µL and a Bland-Altman ratio of 0.99 (95% CI: −0.012–
2.5) demonstrate its robustness and accuracy as internal control (Supplementary File 4). Genomic sequences 
for pfrnr2e2 (PF3D7_1015800), pfhrp2 (PF3D7_0831800) and pfhrp3 (PF3D7_1372200) of Pf3D7 strain were 
obtained from PlasmoDB. A pfhrp2/3 sequence alignment including five reference strains from West-Africa 
(Pf3D7, PfNF54), Guinea (PfNF166.C8), Brazil (Pf7G8) and Cambodia (PfNF135.C10) revealed no SNPs in 
oligo binding regions suggesting a high degree of conservation within the target region of the pfhrp2/3 genes 
(Supplementary Files 2 and 3). The pfhrp2, pfhrp3 and pfrnr2e2 sequences for Pf7G8, PfNF135.C10, PfNF166.C8 
and PfNF54 were obtained from whole genome sequencing34. The Geneious version 8.1.9 software (Biomatters 
Ltd, Auckland, New Zealand) was used for sequence alignments and oligo designs. Relevant information con-
cerning the oligos used in the qHRP2/3-del assay is summarized in Table 1.
Sample analysis with qHRP2/3-del assay. Amplification and qPCR measurements were performed 
using the Bio-Rad CFX96 Real-Time PCR System (Bio-Rad Laboratories, California, USA). The thermal profile 
used for qHRP2/3-del assay is as follows: Taq polymerase activation for 5 min at 95 °C, followed by 45 cycles of 
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15 s at 95 °C and 35 s at 57.5 °C. 2 µL DNA was added to 8 µL reaction master mix containing 1x Luna Universal 
Probe qPCR Master Mix (New England Biolabs, Ipswich, USA) and 1x qHRP2/3-del Primer Mix (Table 1). All 
qPCR assays were run in triplicates with appropriate controls including Non-Template Control and DNA from 
PfDD2, PfHB3 and PfNF54 as controls for the pfhrp2/3 deletion status.
Data management and statistical analysis. Preliminary analysis of qPCR data. Cq values were 
obtained from the Bio-Rad CFX96 Manager 3.1 software (Bio-Rad Laboratories, California, USA) after setting 
the threshold manually. Cq values were transferred and linked to the samples’ metadata using a custom-designed 
database for storage and analysis of qPCR data. Only samples with a Cq ≤ 40.0 for the internal control, pfrnr2e2, 
were considered eligible for analysis of pfhrp2/3 deletion status. ΔCq were calculated by subtraction of pfrnr2e2 
Cq values from pfhrp2 or pfhrp3 Cq values.
Analytical performance of qHRP2/3-del assay and quantification of parasitemia. Based on the PfIS a serial dilu-
tion ranging from 0.01–10’000 parasites/µL was prepared and used to assess the performance of the qHRP2/3-del 
assay. The slope, y-intercept, qPCR efficiency and R2 was established for each target. The Limit of Detection 
(LOD) was defined as the lowest PfIS parasitemia with a positive amplification in 4 out of 6 replicates. Parasitemia 
was estimated using linear regression derived from serial dilution of the PfIS and the pfrnr2e2 target which serves 
as the internal control of the qHRP2/3-del assay.
Graphical representation and statistical analysis. We used R version 3.5.1 for creating ggplot2-based graphs using 
the packages ggpubr, gridextra and scales. The Diagnostic test evaluation calculator (freely available at https://
www.medcalc.org/calc/diagnostic_test.php) was used for analytical validation of qHRP2/3-del assay perfor-
mance. Cohen’s kappa including 95% confidence intervals, providing a measure of agreement, was calculated 
using STATA version 12.0 software (Stata Corp LP; College Station, Texas, USA). P values < 0.05 were considered 
as significant for all statistical analysis.
Ethical approval and informed consent. The samples analyzed in this study were collected in dif-
ferent studies. All studies were approved by the appropriate institutions and informed consent was obtained 
from all participants. The CHMI samples were collected during a clinical study, registered at Clinical Trials.gov 
(NCT02613520), and conducted under a U.S. FDA IND application. The study was performed in accordance with 
Good Clinical Practices. All samples analyzed in this publication were obtained according to the approved study 
protocol. The protocol was approved by the institutional review boards of the Ifakara Health Institute (IHI/IRB/
No: 32–2015), and the National Institute for Medical Research Tanzania (NIMR) (NIMR/HQ/R.8a/Vol.IX/2049), 
by the Ethikkommission Nordwest- und Zentralschweiz, Basel, Switzerland (Ref. No. 15/104), and by the Tanzania 
Food and Drug Authority (Auth. No. TZ15CT013). For the Tanzanian sample collection ethics approval for the 
study was granted by the institutional review boards of Ifakara Health Institute (IHI/IRB/No: 18–2015) and by 
NIMR (NIMR/HQ/R.8a/Vol.IX/2015). For the sample collection from Equatorial Guinea approval was given by 
the Ministry of Health and Social Welfare. The collection, transport and storage of the blood samples from Peru was 
approved by the Human Ethics Committee from Universidad Peruana Cayetano Heredia (UPCH 52707 & 59751).
Data Availability
All data generated or analyzed during this study are included in this published article and its Supplementary 
Information Files.
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Abstract 
Background: Women living in malaria endemic regions particularly in first and second 
pregnancies have higher risk of malaria, with serious adverse effects for the woman and the child. 
To prevent these adverse effects, intermittent preventive treatment with sulfadoxine-
pyrimethamine is recommended during pregnancy. Although rapid diagnostic tests (RDTs) are 
increasingly used during malaria indicator surveys, the test lacks sensitivity for the detection of 
low parasite densities. We describe here the prevalence and molecular characteristics of 
Plasmodium infections in the subpopulation of pregnant women, by utilising the RDTs collected 
during a malaria indicator survey (MIS) on Bioko Island, Equatorial Guinea.  
Methods: We used data and finger-pricked blood samples applied on CareStartTM RDTs collected 
during the MIS 2018 from August to October on Bioko Island from 13505 volunteers. 
Haemoglobin concentrations were measured by HemoCue Hb301 analyzer and results were 
recorded. Nucleic acids were extracted from the used, collected RDTs for downstream quantitative 
polymerase chain reaction (qPCR) assays and Sanger sequencing. 
Results: We found a higher proportion of infections in non-pregnant (15%, 32/208) compared to 
pregnant women (9%, 21/227) detected by both, RDT and qPCR (p=0.05). Four out of 21 (19%) 
and 5 out of 32 (15%) of malaria infections were detected by qPCR only in pregnant and in non-
pregnant women, respectively. Six out of 17 (35 %) and 4 out of 27 (15 %) malaria infections were 
detected by RDT only, in the pregnant and non-pregnant women, respectively, indicative of false 
positive RDTs. Six, four and four women were infected with malaria during their first, second and 
third trimester of pregnancy measured by qPCR. Plasmodium-infected pregnant women without 
clinical symptoms and signs had significantly lower haemoglobin concentrations compared to 
malaria negative, pregnant women.  
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Conclusions: Our study shows that prevalence of malaria infection in pregnant women in 2018 
might be lower than in non-pregnant women, indicate for positive impact of preventive measures 
targeting this population. Plasmodium-infected pregnant women that were asymptomatic were 
more likely to suffer from anaemia underscoring the negative effects of sub-patent malaria 
infections in pregnancy. 
 
Keywords: Prevalence, Malaria, Pregnancy, Intermittent preventive treatment, Quantitative 
polymerase chain reaction, Equatorial Guinea 
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Background 
In 2018, it has been estimated that around 11 millions of pregnancies suffered from a Plasmodium 
falciparum malaria infection in 38 countries in Sub-Saharan Africa (1). Women during their first 
and second pregnancies are more susceptible to malaria compared to non-pregnant adults in 
malaria endemic countries (2). Increased susceptibility to P. falciparum infection during 
pregnancy is related to the sequestration of malaria infected erythrocytes (IE) into the placenta (3). 
The accumulation of IE in the intervillous space is enabled by a combination of slow blood flow 
and binding of IE to the glycosaminoglycan chondroitin sulfate A (3). The parasite encoded protein 
VAR2CSA - belonging to the variable antigen P. falciparum erythrocyte membrane protein-1 
PfEMP1 protein family - interacts specifically with CSA expressed on syncytiotrophoblast cells 
lining the placental intervillous spaces (4). After repeated pregnancies, clinical signs and 
symptoms and prevalence of malaria infection during pregnancy decline significantly (2). This 
acquired immune protection correlates with increasing titers of antibodies targeting VAR2CSA 
that block the binding to CSA and enable phagocytosis of IE (3)(5).  
Severe anaemia, cerebral malaria, preterm delivery or stillbirth usually affects pregnant women in 
low transmission settings. Those living in high transmission settings mainly suffer from maternal 
anaemia and low birth weight of the offspring (6). Malaria associated maternal anemia is a major 
driver of low birth-weight of newborns and WHO estimated that malaria infections in pregnancy 
(MIP) have resulted in an estimated number of 872´000 babies born with low birth-weight in 2018 
(1). Children with low birth weight have a higher risk of death, stunting and poor cognitive 
development later in live (7). Exposure to malaria in utero might promote immune tolerance 
increasing the risk of malaria disease in the infant after birth (8)(9)(10). Although P. falciparum 
causes most of malaria related morbidity and mortality in Sub-Saharan Africa, non-falciparum 
malaria infections also contribute to morbidity in endemic areas and have been described on Bioko 
Island (11)(12)(13).  
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Protection from malaria in pregnancy currently relies on the use of long-lasting insecticide treated 
bed nets (LLINs), intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP) 
and prompt diagnosis and effective treatment (14). IPTp-SP was introduced on Bioko in 2005 and 
has since been implemented in government health facilities through the National Malaria Control 
Program in collaboration with Medical Care Development International (15).  
Diagnosis and surveillance of malaria have traditionally relied on thick and thin blood smear 
microscopy (16). Recently, rapid diagnostic tests (RDTs) that are simple to perform, give rapid 
results, and are deployable in rural settings have been introduced as malaria diagnostic tool (17). 
Most RDTs are based on the detection of circulating histidine-rich protein 2 (PfHRP2) and 
PfHRP3, selectively expressed by P. falciparum (18). RDTs are increasingly used in health care 
settings for prompt diagnosis, but also to measure malaria prevalence during malaria indicator 
surveys (15). The limit of detection of microscopy in expert hands is around 50 parasites/μL, while 
PfHRP2-based RDTs reliably detect parasite densities above 100 parasites/μL (19). RDTs 
therefore lack sensitivity for the detection of low parasitemia which is particularly the case in 
asymptomatic malaria infections in adults (20). Furthermore, P. falciparum isolates lacking the 
histidine-rich protein 2 (pfhrp2) and/or pfhrp3 genes, resulting in false-negative RDTs have been 
reported potentially compromising the usefulness of PfHRP2/HRP3 based RDTs for malaria 
diagnosis (21)(22). The specificity of PfHRP2/HRP3 based RDTs suffers from the extended 
clearance time of the circulating PfHRP2 antigen after successful antimalarial treatment (23). 
Therefore, diagnostic tools with higher sensitivity and specificity such as a nucleic acid (NA) based 
approaches could complement studies investigating malaria prevalence particularly in subclinical 
infections  (20). Here we used RDTs collected from 13505 individuals covering an age range of 0 
– 83 years and inhabiting 4774 selected households during the MIS on Bioko Island in 2018. We 
compare malaria diagnosis based on RDT and using NA extracted from these RDT, subjected to 
qPCR, to describe the prevalence and molecular characteristics of Plasmodium infections in 
pregnant women covering the first, second and third trimester of pregnancy.   
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Methods 
Study area and population  
The study is based on data and samples collected during the MIS conducted on Bioko Island, 
Equatorial Guinea between August 2018 and October 2018. Bioko Island is home to the capital 
city Malabo and located 240 km from the city of Bata on the mainland and 32 km off the coast of 
Cameroon. The surface area of the island is around 2000 km2 with a population of approximately 
335000 people. The MIS survey design and procedures were described previously (24). Briefly, 
all households members present at the time of visit were eligible to participate. Survey questions 
were programmed using DroidDB software, and run on Android-based tablets to collect a wealth 
of information including pregnancy status, antimalarial therapy and history of travel (25). We 
included into the study all women identified as pregnant during the survey and contrasted them to 
non-pregnant women individually matched by age to the pregnant women. 
 
Sample collection and definitions 
Finger pricked blood samples were used to screen for ongoing malaria infection using the 
CareStartTM Malaria HRP2/pLDH (pf/PAN) combo test (ACCES BIO, Inc. 65 Clyde Road 
Somerset, NJ 08873 U.S.A) and haemoglobin concentration was measured with the use of a 
HemoCue Hb301 analyzer (HemoCue AB, Angelholm, Sweden). Using the World Health 
Organization’s classification, severe anaemia was defined as a haemoglobin < 7 g/L and 8 g/dL in 
pregnant and non-pregnant women, respectively (26). Used RDTs were collectively stored at room 
temperature in plastic bags containing desiccants until transport to the Swiss Tropical and Public 
Health Institute for further analysis.  
 
Extraction of nucleic acids 
The Electronic Laboratory Information and Management Utensil for Molecular Diagnostics 
(ELIMU-MDx) platform was used to identify and sort the RDTs from pregnant and non-pregnant 
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women (32). Extraction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) was done 
using the newly developed Extraction of Nucleic Acids from RDTs (ENAR) protocol (33). Each 
96-well extraction plate included one negative control consisting of the Lysis buffer, and one 
positive control RDT at the density of 200 parasites/μL (whole blood was spiked with WHO 
International Standard parasites and applied on RDTs). Total nucleic acids were recovered in 50 
μL of elution buffer (Quick-DNA™ Miniprep Kit, Zymo Research Corporation, Irvine CA, USA) 
and stored in 96-wells DNA plates at -20°Celsius. Extraction of nucleic acids was performed 
within three months of sample collection. 
 
Nucleic acid based malaria diagnosis 
The multiplex PlasQ PCR assay targeting the pan-Plasmodium 18S DNA (Pspp18S) and the P. 
falciparum-specific var acidic terminal sequence genes (PfvarATS) was used to screen for 
presence of malaria and to quantify P. falciparum density (27)(13). For the identification of 
Plasmodium species, we used the PlasID qPCR assay (13). Briefly, to overcome the low amount 
of nucleic acids starting material for the PlasID qPCR assay, we amplified the Pspp18S gene by 
conventional PCR. We performed a Species identification qPCR assay based on the 18S rRNA 
gene. The assay detects all human Plasmodium species except P. falciparum. The following primer 
combinations was used for the pre-amplification of 18S: Pspp18S_RT-HRM_F  GRA ACT SSS 
AAC GGC TCA TT (28), and Pspp_18S_R: AGCAGGTTAAGATCTCGTTCG (PlasQ RT-
qPCR). Briefly, 2 μL of the product from the pre-amplification were added to the master mix 
containing 1x Luna® Universal Probe qPCR Master Mix and 1x Species ID primer mix with a 
total volume of 10 μL. The probes for the species were labelled with following fluorophores: P. 
malariae: Yakima Yellow, P. ovale: Texas Red, P. vivax: Cy5, P. knowlesi: Cy5. The conditions 
for the qPCR were: 95 °C for 3 minutes and 50 cycles of 95 °C for 15 seconds and 60 °C for 45 
seconds. Fluorescence intensity was measured after each cycle. Positive controls for P. ovale and 
P. malariae, P. falciparum DNA as a negative control and a non-template control were included 
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in all runs. In case of a positive Cy5 result, the sample would be run with the same conditions in a 
multiplex assay using the P. vivax Cy5 probe and a probe for P. knowlesi labelled with Quasar 
705. Following nucleotide sequences were used: Pk_18S_Cy5: CTC TCC GGA GAT TAG AAC 
TCT TAG ATT GCT (Cy5)(29), PlasID_Pv18S_Cy5: GAA TTT TCT CTT CGG AGT TTA T 
(30), Pm18SMGBVIC: CTA TCT AAA AGA AAC ACT CAT (Yakima Yellow)(30), and 
Po18S_TxRd_v3.0: GGA 5AT6T CTT AGA TTG CTT CCT 6CAG (Texas Red, 5 = LNA-A, 6 
= LNA-T, unpublished). Samples were run in duplicate and considered positive if one replicate 
out of two showed a clear amplification curve with Cq < 42. All qPCR and RT-qPCR data were 
uploaded to ELIMU-MDx for an automated quality control step and analysis (31).  
 
Data analysis and statistics 
Categorical variables were described with absolute and relative frequencies, and discrete variables 
with medians and interquartile ranges (IQR). Proportions were compared by means of Pearson Chi 
square test and continuous variables by Student’s t-test. Statistical analyses were performed using 
Stata version 14 (StataCorp LP, College Station, TX) and GraphPad Prism version 7 (GraphPad 
Software, La Jolla, USA). 
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Results 
We utilized RDTs collected from 227 pregnant and 208 age-matched non-pregnant control women 
during the malaria indicator survey on Bioko Island in 2018. Study population and malaria 
diagnostic tests used are summarized in Figure 1. Sociodemographic characteristics of the women 
and malaria prevention measures are shown in Table 1. From these RDTs, RNA and DNA was 
extracted following our newly developed protocol (Guirou et al., manuscript submitted). 
 
Figure 1 - Overview of study population and outcome of malaria diagnosis 
Table 1 - Sociodemographic characteristics and malaria prevention used by cohort analysed 
 
Prevalence of Plasmodium spp infection detected by RDT and qPCR 
Plasmodium was detected by qPCR and RDT combined in 15/227 (7%) and 28/208 (13%) 
pregnant and non-pregnant women, respectively (Figure 2). Positive RDTs that tested negative by 
qPCR were found in 6/227 (28%) in the pregnant and 4/208 (12%) non-pregnant women (Figure 
3). RDTs missed 4/21 (19%) and 5/32 (16%) of malaria infections in the pregnant and non-
pregnant women, respectively, since they had positive qPCR results (Figure 3). In addition to P. 
falciparum, four P. malariae infections were detected. Three of the infections were mixed with P. 
falciparum and one was a P. malariae mono-infection. RDT failed to detect the only P. malariae 
mono-infection. No P. ovale nor P. vivax infection was detected (Figure 1).  
 
Figure 2 - Proportions of P. falciparum infections detected by RDT and PlasQ PCR in 
pregnant and non-pregnant women 
 
Figure 3 – Venn Diagram comparing the outcomes of RDT testing with qPCR results based 
on amplification of 18S and PfvarATS 
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Parasite density by PlasQ qPCR 
P. falciparum densities measured by PlasQ qPCR in samples collected from pregnant (n = 21) and 
non-pregnant women (n = 32) are shown in Figure 4. Overall medians of parasite densities were 
low (< 100 parasites/µL) in all RDTs tested (Range: 0.3 - 2165 parasites/ µL) and did not 
significantly vary between the pregnant and the control groups (Mann Whitney test, p = 0.29). 
Parasite densities in samples tested positive by both RDT and qPCR were significantly higher 
compared to samples tested positive by qPCR only (Mann Whitney test, p = 0.038). Conversely, 
infections missed by RDT were of low parasite density (Range: 0.4 to 94 parasites/µL) (Figure 
4A). Six, 4 and 4 malaria infected pregnant women were in their first, second, and third trimester 
of pregnancy, respectively. Median parasite density was slightly lower in the first compared to the 
second and third trimesters of pregnancy (Figure 4B).  
 
Figure 4 - Parasite densities in infected women 
 
Anemia in malaria infected pregnant women 
Mean haemoglobin concentration was 10.9 ± 1.4 g/dL among the pregnant and 11.8 ± 1.5 g/dL in 
the non-pregnant group. Haemoglobin concentration was significantly lower in malaria infected 
(10.0 ± 0.3 g/dL) compared to non-malaria infected pregnant women (11.0 ± 0.1 g/dL), t-test, p = 
0.012, in the pregnant but not in the control group (t-test, p = 0.21) (Figure 5).  
 
Figure 5 – Anemia in pregnant women is associated with malaria infection 
 
Factors associated with Plasmodium infection  
Next, we tried to understand risk factors associated with malaria infection in pregnant women. The 
proportion of women who reported sleeping under a mosquito net the night preceding the survey 
was higher in the pregnant compared to the control group (Table 1). The proportion of women 
 84 
who reported being sick was 26.7% in qPCR-positive and 9.4% in qPCR-negative pregnant 
women. Plasmodium infection was associated with sickness within two weeks prior to survey in 
the pregnant (Chi-square test, p = 0.036) but not in the control group (Chi-square test, p = 0.76). 
 
Discussion  
We used RDT in combination with NA based diagnostic assays to determine the prevalence of P. 
falciparum and non-falciparum species in pregnant and age matched non-pregnant women in 
samples collected as part of MIS2018. The sensitivity of the CareStartTM Malaria HRP2/pLDH 
(pf/PAN) combo test is around 100 parasites/µL and we set out to understand how many infections 
might be missed, particularly in pregnant women, by using a more sensitive qPCR based diagnostic 
test developed by our group (Guirou et al., manuscript submitted). Molecular testing added to the 
44 RDT positive women an additional 9 cases that have been missed by RDT (17%) supporting 
the idea that the PlasQ qPCR is more sensitive than RDT. 
Ten women tested positive by RDT only and in the absence of confirmation by qPCR, we consider 
these tests as false positive. We did not find any association between RDT false-positivity and 
prior treatment in pregnant women in contrast to previous reports (23)(32). One possible 
explanation is that the RDT detected HRP2 released from IE that sequestered in the placenta with 
very low numbers of parasites circulating in the periphery - therefore remaining largely 
undetectable in peripheral blood (33). Overall, the prevalence of Plasmodium infection (RDT and 
qPCR positive samples combined) in our cohort was 12% which is in agreement with malaria 
prevalence reported (15). We found a higher proportion of infections in non-pregnant (15%, 
32/208) compared to pregnant women (9%, 21/227) detected by both, RDT and qPCR (p=0.05). 
These result indicate that the IPTp-SP program implemented on Bioko Island through the National 
Malaria Control Program reduces malaria infections in this highly vulnerable population. The 
implementation of targeted preventive interventions by the Bioko Island Malaria control program 
including distribution of bed nets, administration of IPTp-SP, and delivery of educational 
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messages to pregnant women has been conducted since 2005 (15). Among the pregnant women 
eligible for IPTp-SP at the time of the survey, 69, 38, and 36% took at least one, two and three 
doses of SP, respectively. These figures compare favourably to reports from other malaria endemic 
countries where lower numbers of pregnant women are reached by the IPTp-SP (34)(1). 
Four P. malariae infections were detected in our cohort confirming that P. malariae is prevalent 
on Bioko Island (13)(35). Little is known about the effect of P. malariae infections in pregnancy, 
warranting further investigations of impact of non-falciparum species on clinical signs and 
symptoms of the population living on Bioko Island (11). No P. ovale and P. vivax parasites were 
detected in the 43 women tested. 
Clearly, the major limitation of our study is the small volume of blood applied on RDT (~ 5 µL) 
which reduces the sensitivities of the qPCR assays used. Medians of parasite densities were below 
the reported lower limit of detection of the CareStartTM Malaria HRP2/pLDH (100 parasites/µL) 
when assessed by PlasQ qPCR and ranged from 0.3 to 2165 parasites/µL. P. falciparum parasite 
densities were not significantly higher in pregnant women compared to non-pregnant women and 
parasite densities did also not significantly vary according to parity or age of pregnancy. Albeit 
our total number of P. falciparum positive pregnant women is low, it is important to note that more 
qPCR-positive women were detected during the first compared to the second and third trimesters 
of pregnancy, supporting previous reports highlighting the importance of malaria infection early 
during pregnancy (36)(34). 
Despite the low prevalence of malaria infection, Plasmodium-infected, pregnant women had 
significantly lower haemoglobin concentrations, confirming that malaria infection in pregnancy - 
even in the absence of clinical symptoms and at low parasite density - constitute an important risk 
factor for maternal anaemia (37). In contrast, there was no association between malaria infection 
and haemoglobin concentration in the non-pregnant women. Hence, malaria in pregnant women 
on Bioko Island is a driver for anaemia emphasizing the importance of preventing malaria and 
prompt treatment in this vulnerable group.  
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Conclusions 
Our study shows that the prevalence of malaria infection in pregnant women was lower than in 
non-pregnant women on Bioko Island. This finding underscores that implementation of preventive 
measures targeting this vulnerable population is effective. Using the MIS2018, we are identify 
malaria infected women in their first trimester. These women should be encouraged to come to 
health facilities early.  Although less pregnant women were infected with P. falciparum, they were 
more likely to suffer from anaemia.  
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Table 1 - Sociodemographic characteristics and malaria prevention used by cohort analysed 
  Pregnant women 
(N = 227) 
Non-pregnant women 
(N = 208) 
Age, Median (IQR) 26 (21- 31) 25 (21 - 31) 
 
n % n % p-value 
Parity 
     
Primi-secundiparae 107 48.4 127 62.9 0.002 
Residence  
     
  Malabo  180 79.3 169 81.3 0.6 
  Baney 32 14.1 29 13.9 0.95 
  Luba 8 3.5 6 2.9 0.72 
  Riaba 7 3.1 4 1.9 0.42 
Socioeconomic status 
     
  1-Wealthiest 39 17.2 25 12.0 0.12 
  2-Wealthy 44 19.4 40 19.2 0.95 
  3-Medium 54 23.8 44 21.2 0.51 
  4-Poor 40 17.6 52 25.0 0.06 
  5-Poorest 50 22.0 47 22.6 0.88 
Mosquito net use 137 60.4 89 42.8 0.001 
≥ 2 doses of IPT-SPa 43 58.1 
   
≥ 3 doses of IPT-SP 20 27.0 
   
a Doses of IPTp-SP received by women in the second and third trimester of pregnancy  
IQR: interquartile ranges, Socioeconomic status defined by using principal components analysis 
of household assets and amenities.  
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Chapter 5 
HIV infection negatively impacts the vaccine efficacy of whole irradiation attenuated 
sporozoite based malaria vaccines when evaluated by homologous controlled human 
malaria infections 
 
This chapter contains the following working manuscript: 
 
Etienne Guirou et al. HIV infection negatively impacts the vaccine efficacy of whole 
irradiation attenuated sporozoite based malaria vaccines when evaluated by homologous 
controlled human malaria infections.
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HIV infection negatively impacts the vaccine efficacy of whole irradiation attenuated 
sporozoite based malaria vaccines when evaluated by homologous controlled human 
malaria infections 
 
This is a working manuscript, which is currently not ready to be submitted to a peer reviewed 
journal since the clinical study has not been published by the study sponsor, Sanaria Inc. 
 
 
Abstract 
Malaria and HIV are co-endemic in many regions of Sub-Saharan Africa. Deployment of a 
malaria vaccine in the general population will require that the vaccine is safe and efficacious in 
all volunteers, irrespective of their HIV infection status. Here, we have vaccinated a group of 
HIV positive and HIV negative volunteers in Tanzania with irradiation attenuated purified 
Plasmodium falciparum sporozoites to compare the safety, immunogenicity and protective 
efficacy against homologous controlled human malaria infection. This is the first time that HIV 
positive volunteers have undergone controlled human malaria infection providing the 
opportunity to understand under highly controlled conditions the interaction between HIV and 
malaria. This trial has been registered at ClinicalTrials.gov Identifier: NCT03420053. 
 
 
Keywords: Controlled Human Malaria Infection (CHMI), Human immunodeficiency virus 
(HIV), Rapid diagnostic test (RDT), quantitative polymerase chain reaction (qPCR), thick 
blood smear (TBS) microscopy, Plasmodium falciparum, PfSPZ Challenge 
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Introduction: 
 
Malaria remains a disease of global health importance, despite the gains made during the last 
decade in reducing morbidity and mortality. The latest estimates of the burden of malaria 
indicated that 228 million cases and over 405 000 deaths from malaria globally in 2018 deaths 
(1). Vector control by impregnating bed nets and spraying indoor surfaces of houses with 
insecticides is the primary intervention for decreasing malaria transmission at the community 
level. However, the increased resistance of mosquitoes to insecticides such as pyrethroids is a 
challenge to current vector control measures (2).  Despite encouraging progress made in some 
areas of Africa, malaria elimination will likely require an effective vaccine ((3)). Based on 
previous evidence that attenuated whole Plasmodium falciparum sporozoite (PfSPZ) induced 
high level, durable protection (4). Sanaria Inc. developed aseptic irradiation attenuated 
cryopreserved PfSPZ as vaccine candidate. PfSPZ-based vaccines were safe, well tolerated and 
protective in many studies ((5) and could be used in mass vaccination programs for malaria 
elimination. Because HIV infection shows a significant geographic overlap with malaria in sub-
Saharan Africa (6), it is important to assess the safety, tolerability and efficacy of the vaccine 
in the HIV infected individuals. Both malaria and HIV case management involve combination 
therapies, and interactions between antiretroviral treatment and antimalarials also deserve 
attention (7). Clinical development is time consuming and costly, therefore Controlled human 
malaria infection (CHMI) offers an opportunity to select pre-erythrocytic vaccine candidates 
with potential efficacy using experimental controlled conditions (8). CHMI entails the 
deliberate inoculation by syringe and needle of live infectious sporozoites to healthy human 
volunteers. Such infections have been recently carried out in many malaria endemic countries 
including Bagamoyo, Tanzania (9). Following inoculation, parasitemia are closely monitored 
by thick blood smear microscopy and by quantitative polymerase chain reaction (qPCR) to 
ensure that volunteers are treated before the appearance of malaria symptoms. Here we report 
for the first time on the safety, immunogenicity and vaccine efficacy (VE) against CHMI of 
irradiation attenuated whole P. falciparum sporozoite based vaccine (PfSPZ Vaccine) in HIV 
negative and HIV positive Tanzanian adults. 
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Material and Methods: 
 
Study design and population  
This was a single center randomized, double-blind, placebo-controlled trial designed to assess 
the safety, tolerability, immunogenicity and efficacy of Sanaria’s radiation attenuated PfSPZ 
Vaccine in HIV negative and HIV positive volunteers in Bagamoyo, Tanzania (Clinical 
Trials.gov: NCT03420053). In total, 21 male and female adult volunteers aged from 18 to 45 
years were enrolled and 18 of them underwent CHMI. Nine volunteers comprising six vaccinees 
and three placebo controls were enrolled into each group. HIV positive volunteers were on 
stable anti-retroviral therapy (ART) for at least 3 months with a CD4+ cell count above 500 
cells/μL at screening. Volunteers in the vaccine group received 900’000 aseptic, purified, 
metabolically active, live, radiation attenuated cryopreserved P. falciparum sporozoites 
(PfSPZ) administered intravenously at 0, 2, 4, 6 and 28 days. Controls received parallel 
injections with normal saline to keep blinding. 
 
Controlled Human Malaria Infection 
Homologous CHMI (PfSPZ Challenge) was conducted by intravenous administration of 3200 
infectious aseptic, purified, cryopreserved NF54 P. falciparum sporozoites approximately 3 
weeks after the last dose of PfSPZ candidate vaccine to assess protective efficacy. Parasitemia 
was checked twice daily from day 8 to 14 and then once daily through day 20 post CHMI. 
Volunteers diagnosed with malaria were treated and discharged. Volunteers not positive by the 
end of the observation period (day 20), were discharged and scheduled for a follow-up clinic 
visit on day 28 post CHMI. Those who remained negative throughout day 28 of follow-up were 
presumptively treated with antimalarials.  
 
Parasite detection and quantification 
Thick blood smear microscopy (TBS) microscopy was performed as previously described (10)  
The PlasQ qPCR assay was used in parallel to TBS to determine and quantify parasite density 
during the CHMI study as described (11). 
 
CD4+ counts and HIV-1 viral load assessment 
Throughout the immunization period and the CHMI, among the HIV+ volunteers the CD4+ 
counts and the HIV viral loads were closely monitored. CD4+ counts were obtained by FACS 
(BD Biosciences, California, USA). The Xpert HIV-1 VL assay (Cepheid, California, USA) an 
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automated molecular test which uses the GeneXpert systems was used to assess HIV viral loads 
in 1 mL plasma according to the manufacturer’s instructions.  
 
Anti-PfCSP antibody assays  
Blood for immunogenicity testing was drawn prior to the first immunization and 2 weeks after 
the final immunization. Serum was separated and frozen at -80°C within 4 hours of collection. 
IgG antibodies to Pf circumsporozoite protein (PfCSP) were assessed by ELISA as described 
(10). 
 
Data management and statistical analysis 
The qPCR assays were run on a Bio-Rad CFX 96 Real-Time instrument using CFX Maestro 
Software (Bio-Rad Laboratories, California, USA). qPCR raw data was managed and analysed by 
our in-house qPCR-specific laboratory management and information system ELIMU-MDx (12). 
Parasite densities based on the P. falciparum-specific PfvarATS qPCR assays were used to calculate 
parasite multiplication rates (PMRs). PMRs were modelled using a linear model fitted to log10-
transformed qPCR data as previously published(13). PMR was calculated for all volunteers that 
developed blood-stage parasitaemia which lasted for at least two 48-hour cycles. Data was analysed 
and plots created using Graphpad Prism software version 9. 
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Results: 
 
HIV infection is associated with reduced immunogenicity and vaccine efficacy of PfSPZ 
Vaccine 
All volunteers successfully finalized the vaccination period without any safety signals 
observed. Three weeks past last vaccination, the volunteers underwent CHMI using 3200 fully 
infectious purified sporozoites. As shown in Figure 1, all placebos developed asexual blood 
stage parasitemia detected by qPCR, but not by TBS microscopy. While 5 out of 6 vaccinated 
volunteers were protected in the HIV negative cohort (n=6), all HIV positive vaccinees 
succumbed to malaria infection and developed asexual blood stage parasites.  It is well known 
that HIV infection results in immunosuppression. We therefore compared the anti-CSP 
antibody responses in vaccinees versus placebos in both cohorts (Figure 2). Surprisingly, no 
difference in antibody titers binding to CSP could be observed in HIV positive and HIV 
negative volunteers 2 weeks past last vaccination, representing the peak time point of serum 
antibody responses induced after whole sporozoite based vaccination.  
 
HIV infection status does not impact the blood-stage malaria parasite growth dynamics 
Next we wanted to understand if asexual blood stage parasites grow faster in HIV positive 
versus HIV negative volunteers during CHMI. In Table 1, the prepatent period as measured by 
qPCR and TBS is shown for HIV positive and HIV negative volunteers (vaccinees and placebos 
combined). The peak parasitemia and parasite multiplication rates are given. No significant 
difference in the prepatent period, peak parasitemia and parasite multiplication rates could be 
established. Figure 3 shows the growth patterns of asexual blood stage parasitemia over time 
as measured by qPCR for each of the volunteers stratified by vaccination and HIV infection 
status. 
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Table 1: 
 HIV- volunteers 
positive for Pf during 
CHMI (n=4) 
HIV+ volunteers 
positive for Pf 
during CHMI (n=8) 
P value 
Prepatent period by qPCR (average and 
range) 
10.0 (9.5-11.0) 12.3 (8.5-18.0) 0.18 
Prepatent period by TBS (average and 
range) 
14.5 (12.0-18.0) 16.2 (13.0-18.0) 0.23 
% of volunteers with sub-microscopic 
infections 
0.0 (0/4) 37.5 (3/8) 0.17 
Peak parasite density in Pf/µL 
(geometric mean) 
2.9 ± 4.8 5.6 ± 77.3 0.94 
Parasite multiplication rate 5.7 ± 3.0 8.9 ± 4.2 0.21 
 
 
Controlled human malaria infection does not affect low and stable HIV viral loads 
We assessed potential changes in HIV viral load before, during and after (day 56) CHMI. As 
shown in Figure 4, two volunteers developed during CHMI HIV viremia that could be measured 
by GenXpert. On day 56, all volunteers had returned to undetectable HIV viral loads in the 
serum samples collected. CD4 T cell counts of these volunteers remained also stable, with only 
volunteer 054-51 displaying during CHMI a drop below 500 cells/microliter (Figure 5).  
 
HIV+ participants experienced malaria re-infection after completion of CHMI 
We found that 50% (4/8) HIV+ volunteers were re-infected with P. falciparum after completion 
of the CHMI which included a full course of anti-malarial treatment. Among the HIV- 
volunteers not a single re-infection was observed (Fisher’s exact test, p value = 0.0769) on day 
56. These data clearly show that HIV infection is a driver of increased malaria infection as 
described previously (7). 
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Discussion: 
 
To our knowledge, this was the first time HIV positive volunteers were immunized using PfSPZ 
Vaccine with the VE assessed against homologous CHMI. PfSPZ vaccine was well tolerated 
and safe but less immunogenic and protective in HIV positive Tanzanian volunteers than in 
HIV negative volunteers. Strikingly, the anti-CSP antibody response did not differ significantly 
between the two vaccination cohorts, stressing the importance of cell mediated immune 
mechanisms in PfSPZ vaccine induced protection (14). The PfSPZ vaccine was given five times 
in a shortened regimen comprising 28 days. This novel shortened regimen has the advantage of 
providing VE in a short time frame that will foster compliance of vaccinees in the field. During 
the vaccinations, no vaccine induced safety signal could be observed in all volunteers stressing 
the safety of PfSPZ vaccine as  observed in a number of previous studies (11)(10)(15)(16). 
During CHMI, all HIV positive volunteers developed asexual blood stage parasitemia that 
however did not seem to activate the HIV infection as would be reflected by an increase in the 
HIV viral load. Also, CD4 T cell counts were not affected during the single controlled malaria 
episode demonstrating that the safety of the volunteers have not been jeopardized during the 
study. Some Tanzanian volunteers included showed pre-existing immunity against malaria 
since they contained low parasitemia levels that never reached TBS microscopy threshold. This 
observation stresses the importance of molecular diagnosis of malaria infections during vaccine 
efficacy studies in malaria pre-exposed volunteers.   
 
Figure legends: 
 
Figure 1:  
Kaplan-Meier curves in volunteers undergoing CHMI as assessed by TBS (A) and by qPCR 
(B). 
 
Figure 2:  
Antibodies to PfCSP by ELISA. IgG antibodies to Pf circumsporozoite protein PfCSP by 
ELISA two weeks after the 5th dose by HIV status and vaccination group. Antibody responses 
are reported as the net OD1.0 or the difference between the post and pre-immunization OD 1.0. 
Filled circles represent volunteers remaining uninfected after CHMI; open circles represent 
volunteers infected after CHMI. Antibody responses to PfCSP were significantly higher in the 
PfSPZ Vaccine group than in the Control group by vaccination status (Mann Whitney test, 
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p=0.02). Antibody response did not differ significantly between HIV positive and HIV negative 
vaccine recipients groups (Mann Whitney test, p=0.24). 
 
Figure 3: 
Parasite density as measured by qPCR given by HIV status and trial group after CHMI. The 
dashed lines represent the lower limit of qPCR positivity. Parasite densities are plotted with an 
offset of 0.05 parasite/µL. 
 
Figure 4:  
HIV Viral load in HIV positive volunteers before, shortly and long after CHMI. Before: 1-2 
days before CHMI; short: 13-20 days after CHMI, long: 56 days after CHMI. Detectability of 
viral load: 0 = not detected, 1 = detected. Viral loads did not significantly vary before and after 
CHMI (Wilcoxon matched-pairs signed rank test, p=0.5).  
 
Figure 5: 
CD4 count in HIV positive volunteers before, shortly and long after CHMI. Before: 1-2 days 
before CHMI; short: 13-20 days after CHMI, long: 56 days after CHMI. CD4 count did not 
significantly vary before and after CHMI (Wilcoxon matched-pairs signed rank test, p=0.5).   
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Chapter 6 
 
General discussion 
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6.1 The importance of implementing molecular tools in malaria surveillance programs 
 
In almost all endemic countries, malaria surveillance is limited to obtaining the parasite 
prevalence among sentinel or vulnerable sub-populations, such as schoolchildren, by either 
microscopy or malaria rapid diagnostic tests (RDTs). This data is being used to evaluate 
intervention programs and provides the framework for effective allocation of resources (79). 
With the spread of P. falciparum genotypes resistant against artemisinin-based combination 
therapies (ACT) and strains carrying pfhrp2 deletions and therefore escaping detection by 
widely used malaria RDTs, new serious threats to malaria control and elimination efforts 
around the world have recently emerged (108). WHO reports that delay in malaria diagnosis 
and treatment is the leading cause of death. Georeferenced information about the presence, 
prevalence and risk factors associated with these strains threatening current control approaches 
of malaria should be included in malaria surveillance programs. Implementing a molecular 
surveillance approach offers a unique opportunity to support policy makers regarding the 
choice and change of drugs and tests for malaria diagnosis and treatment before resurgence of 
malaria occurs.  
 
6.2 Why extract nucleic acids from used malaria rapid diagnostic tests? 
 
Early and accurate diagnosis is essential for effective management of malaria at the individual 
level for travellers and people living in malaria endemic countries. Microscopic examination 
of Giemsa-stained thick and thin blood films remained for long time the only available 
diagnostic tool for parasite identification and is still regarded as the gold standard. This 
technique that screens essentially 2 to 6 microliters of blood for parasites has shortcomings 
including low sensitivity (in the range of 50-100 parasites per µL of blood), requirement of 
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continuous training, maintenance of equipment, dependency on electricity supply and time 
required for careful preparation of slides and reading (109). As an alternative, lateral-flow 
based immunochromatographic devices known as RDTs that are point-of-care tests have been 
developed to overcome these limitations, particularly in resource poor settings. Currently 
available RDTs are performed using 5 – 10 microliter of blood, easy to perform, provide a 
result within 20 minutes, achieve a sensitivity of ~100 to ~1000 parasites per µL of blood 
depending on the target protein used (110) (111) and are widely deployed in malaria endemic 
countries (112). Apart from point-of-care patient care, RDTs are increasingly deployed for 
routine malaria surveillance in malaria control programs to monitor malaria prevalence trends 
either in the general population or particularly vulnerable population like children under five 
years of age or pregnant women (113). Clear limitations of RDTs are not only the lack of high 
sensitivity but also the difficulty to diagnose non-falciparum species prevalent in West African 
countries like P. malariae and P. ovale spp. lacking HRP2 and HRP3 expression (114). Malaria 
surveillance is essential to generate information on malaria prevalence data over time that are 
used for planning, implementing, monitoring and evaluating malaria programs. As 
transmission decreases, malaria becomes focal, and the intensity and frequency of reporting 
should increase until final elimination has been achieved (79). Accurate parasitological 
diagnosis of a malaria case is instrumental in a malaria surveillance system and as countries 
strive to move towards malaria elimination, more sensitive malaria tests are needed to find the 
reservoirs of residual transmission (115, 116). 
 
Molecular techniques based on nucleic acid amplification have been developed that are way 
more sensitive than RDTs or microscopy for malaria detection (117). Molecular techniques can 
easily be adapted to novel targets for amplification and allow the discrimination of the different 
human infective Plasmodium species (118). One widely used method of blood sample 
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collection for molecular assays include the collection and storage of around 50 microliter of 
capillary blood on filter papers (119). If higher blood volumes are needed, several spots on a 
filter paper can be spotted with one single finger pricked sample, allowing for up to 200 
microliters of blood stored. Therefore, when compared to RDTs, around ten to twenty times 
more blood on a filter paper could be stored increasing the chance of parasites to be collected. 
The disadvantage of using filter papers is that high-quality papers are costly, are usually 
distributed by specific research projects, require good storage conditions and do not easily fit 
into routine work of malaria surveillance since more blood needs to be collected (119). In the 
laboratory, high-throughput extraction of DNA from filter papers are best performed by the use 
of a robotic based extraction platforms (120). 
 
In the course of this thesis, we attempted to combine the broad availability of RDTs in the field 
with the higher sensitivity and quantitative measurement of Plasmodium spp. by using the RDT 
nitrocellulose strip included in the malaria RDTs as carrier for nucleic acids (NA). Previous 
studies have shown that DNA extracted from RDTs were similar in quality and quantity to 
those obtained from blood applied onto filter papers in direct side to side comparisons (121, 
122). Methods developed over the years for DNA extraction from used RDTs are summarized 
in Supplementary Table 1 of the manuscript presented in Chapter II (Guirou et al.,). In this 
work, we have first systematically compared and then adapted different protocols for extraction 
of NA to arrive at a high throughput method to co-purify DNA and RNA from RDT with 
limited hands on requirements. We made an important improvement of the currently described 
extraction method by using the entire nitrocellulose strip directly from the RDT without any 
manipulation. By removing the manual cutting of the nitrocellulose strip we reduce the 
processing time, and more importantly, the potential risk of sample cross-contamination by 
carryover between samples. Our extraction procedure takes around 3 hours, including the 2 
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hours needed for the incubation period in the extraction buffer. Therefore, following our 
approach will easily allow to extract 1000 RDTs per week, making it an unprecedented method 
for molecular malaria surveillance. The possibility of modifying our current method by 
including a robotic-based extraction platform could further facilitate the use of NA extracted 
from RDTs in molecular epidemiology studies. Another advantage of combining NA extracted 
from RDT with molecular assays is the possibility to conduct several experiments using the 
same sample. 
 
We did not find conclusive evidence that longer-term storage of RDT has a negative impact on 
the detection rate of P. falciparum if initial parasite density spotted on the RDT was above 10 
parasites/µL. This is similar to reports in previous studies. This provides the opportunity to 
conduct retrospective molecular studies over several years using RDTs collected and stored at 
room temperature (123). After having established a high-throughput extraction method for 
RNA and DNA from RDT, we were able to extract around 3000 RDTs samples from a malaria 
indicator survey in 2018 on Bioko Island. The lower limit of parasite detection of our method 
is 1 parasite/µL of blood applied to the RDT. This represents around 100 times higher 
sensitivity compared to diagnosis based on RDT only and will certainly help to identify more 
sub-microscopic malaria infections in the field. 
One of the bottlenecks during the process of analysing high numbers of samples using 
molecular diagnosis is management and analysis of data. This problem has been tackled by the 
development of software applications described in Chapter II of this thesis. We developed two 
apps, which support sorting and tracking barcoded RDTs during the extraction process using a 
smartphone’s camera. For high-throughput data analysis the ELIMU-MDx platform was 
developed during this thesis allowing automatized quality control of qPCR data generated plus 
the central storage of protocols, reagents and final results (124).  
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In summary, our study demonstrates the feasibility of extracting NA from thousands of RDTs 
and to analyze from one single sample not only presence or absence of malaria, but add 
essential information including (i) parasite quantity, (ii) P. malariae and P. ovale spp. 
prevalence, (iii) prevalence and type of synonymous or non-synonymous mutations in the 
kelch13 propeller region and (iv) to search for hrp2/hrp3 gene deletion carrying P. falciparum. 
In combination with the ELIMU-MDx platform we have developed a powerful analysis 
pipeline for molecular surveillance of malaria that can be still expanded for additional questions 
such as parasite genotyping or gametocyte detection. 
 
6.3 Monitoring Plasmodium falciparum strains lacking histidine-rich protein 2 and 3 
genes 
 
Work towards an HRP2-based immunochromatographic RDT began during the early 1990s 
(125). In 1993, WHO published the Global Plan of Action for Malaria Control stressing the 
need for improvement of parasitological diagnosis at the peripheral and community level (126). 
PfHRP2 and PfHRP3 are expressed at high levels during the asexual blood stage cycle, with 
rapid increase during the ring-stage and slower accumulation in the trophozoite and schizont 
stages (127). In 2004, less than 1 million malaria RDTs have been used, however by 2013 more 
than 300 million were being sold yearly. This exponential growth of RDT sales was associated 
with the development and usage of the new artemisinin combination therapies (ACT) (59). In 
2012, WHO launched the T3 initiative: Test. Treat. Track to scale up diagnostic testing, 
treatment and surveillance for malaria (128). Manufacturers surveyed by WHO for the World 
malaria report 2018 reported a total of 276 million RDT sales in 2017. Most RDTs (66%) were 
supplied to sub-Saharan Africa and in 2017 roughly 75% of malaria tests in sub-Saharan Africa 
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were conducted using RDTs. In areas of declining malaria transmission, parasitaemia is often 
below the level of detection of microscopy and standard RDT (50 - 200 parasites/microliter). 
However, it is thought that these sub-clinical infections contribute to malaria transmission, 
pushing need for better diagnostic tests (129). Ultrasensitive HRP2-based RDTs (uRDTs) with 
enhanced signal detection methodology have a detection threshold of < 10 parasites/microliter 
(130). These uRDTs might improve detection of these low-density parasite infections, but will 
not improve the diagnosis of clinical malaria cases (131, 132). P. falciparum strains carrying 
pfhrp2/3 gene deletions and therefore evading detection by HRP2/HRP3 based RDTs pose a 
serious threat to malaria control and elimination programs globally (133). Together with the 
emergence and spread of artemisinin resistant strains, these parasites are a powerful example 
that molecular assay based surveillance approaches have to be implemented in malaria control 
programs to monitor potential increase in prevalence over time due to their selective growth 
advantages based on either escaping diagnosis or treatment. Studies on pfhrp2/3 gene deletions 
in African countries have found a wide range of prevalence reported. A study conducted in 
Eritrea found a high prevalence of pfhrp2 gene deletions, many of them also lacked pfhrp3 
(134). HRP2 antigen was absent from these samples, leading to false negative PfHRP2 based 
RDTs and the need for replacement of the diagnostic tool (134). In the Democratic Republic 
of the Congo a prevalence of 6.4% P. falciparum with hrp2 gene deletions was reported (135). 
A study in Mozambique found only 1.4% pfhrp2 gene deletions and no pfhrp3 deletion (136). 
A study conducted in Kenya did not find any pfhrp2 or pfhrp3 gene deletions, but reported a 
high proportion of polyclonal infections (137). A different study in Kenya found 9.0% pfhrp2 
and 1.1% pfhrp3 gene deletions, respectively, in 89 samples by PCR (138). These deletions 
were confirmed by analysing the pfhrp2 and pfhrp3 genomic loci in greater detail, with the 
pfhrp2 and pfhrp3 gene deleted samples missing either the respective gene or also flanking 
regions (138). One caveat in all these studies is that many infections are multiple strain 
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infections in Africa, meaning that a strain carrying a pfhrp2 gene or pfhrp3 gene deletion might 
be masked by the second strain that does not lack these genes.  
 
We have developed during this thesis a novel assay named qHRP2/3-del suitable for high-
throughput screening of P. falciparum isolates carrying pfhrp2 and/or pfhrp3 gene deletions. 
Major advantages of the novel assay over currently used sequentially performed nested PCR 
assays include rapidity, ease of performance, and the determination of parasite density. 
Importantly,  the assay allows the detection of pfhrp2 and pfhrp3 gene deletions in multiple 
strain co-infections that are particularly prevalent in Sub-Saharan countries (139). We have 
started to implement the qHRP2/3-del assay to field samples from Equatorial Guinea. We are 
currently focusing on RDTs collected from children under five years of age in the malaria 
indicator survey 2018 that are suffering from anemia and have a negative RDT result. This is 
intended to identify diagnostic resistant parasites that lack HRP2 and HRP3 production using 
our newly developed qPCR based read out. With growing availability of qPCR instruments in 
reference laboratories in Sub-Saharan countries, our novel assay could be used as a surveillance 
tool to monitor over time the potential expansion of P. falciparum strains carrying pfhrp2/3 
deletions.   
 
6.4 Molecular surveillance of malaria in pregnant women on Bioko Island 
 
We used our newly established analysis pipeline to determine the prevalence of P. falciparum 
and non-falciparum species in pregnant and age matched non-pregnant women on Bioko Island 
in 2018. We were able to utilize the RDTs collected as part of a malaria indicator survey and 
analysed in total 435 RDTs within less than four weeks of laboratory-based work. Advantages 
of targeting specifically pregnant women for malaria surveillance include the ease of access 
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because these women supposedly attend antenatal care facilities several times during 
pregnancy where blood sampling is possible and their regular inclusion in household malaria 
surveys (140, 141). However, the true burden of pregnancy-associated malaria is most likely 
underestimated because women attend antenatal care facilities later during their pregnancies, 
therefore missing out often women in their first trimester of pregnancy (142, 143). In addition, 
parasitaemia levels in peripheral blood can be low due to the specific sequestration of P. 
falciparum-infected red blood cells into the placenta through CSA and VAR2CSA interactions 
(44, 55). 
 
While our sample size in this study is still small, we could demonstrate that the IPTp-SP 
program implemented on Bioko Island contributes to reduction of P. falciparum infections in 
pregnant women when compared to age matched non-pregnant controls. NA isolated from 
several malaria positive RDTs did not yield a positive qPCR result for P. falciparum. These 
RDTs could be either false positives RDTs based on the circulation of HRP2 after malaria 
treatment completion (142) or be real positive based on the fact that the RDT detected HRP2 
released from parasites sequestered in the placenta that are undetectable by qPCR (71, 144). 
Importantly, Plasmodium-infected, pregnant women had significantly lower haemoglobin 
concentrations compared to their uninfected counterparts, confirming that malaria infection in 
pregnancy - even in the absence of clinical symptoms and at low parasite density - constitutes 
a cause of maternal anaemia (145). Also, we were able to identify women in the first pregnancy 
trimester with malaria infections some of them have been missed by RDT based on the low 
parasitaemia. These women are vulnerable to the effects of malaria infections and should be 
included into the malaria treatment programs as early as possible (143, 146). We intend to 
expand this study in 2020 by adding the RDTs collected from pregnant women during the 
malaria indicator survey conducted in 2019. Since malaria prevalence as defined by RDT 
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positivity has increased up to 19 % in the general population in 2019 (unpublished result) we 
would like to understand if pregnant women are affected by this upward trend in malaria 
prevalence on Bioko Island.  
 
6.5 Following Plasmodium falciparum parasitaemia in HIV positive volunteers 
undergoing CHMI 
 
Chapter 5 of this thesis contains parasitaemia data which was obtained during controlled human 
malaria infection (CHMI) study conducted in Bagamoyo, Tanzania. The major concern during 
this study was safety, since this was the first time ever CHMI was tested in HIV positive 
volunteers. Therefore, real-time parasitaemia during the CHMI was not only monitored by 
thick blood smear (TBS) microscopy, but also qPCR. This allowed us to study the interaction 
between the P. falciparum parasites and the HIV virus under controlled conditions. No negative 
short- or long-term impact on HIV viral loads or CD4+ counts was observed upon CHMI. 
There is also no evidence that P. falciparum parasite growth dynamics were different between 
HIV positive and HIV negative volunteers. We concluded that CHMI was safely conducted in 
HIV positive volunteers who are under antiretroviral therapy and have stable CD4+ counts and 
low HIV viral loads. The importance of this study should not be underestimated since it 
provides additional evidence for the safety of CHMI and the understanding of co-infections 
between two major infectious diseases prevalent in Sub-Saharan Africa. 
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Chapter 7 
 
Conclusion and Outlook 
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Conclusion and Outlook 
 
Point of Care rapid diagnostic tests based on detection of HRP2 secreted by asexual blood stage 
parasites have become one of the corner stones of malaria control. The switch from the gold 
standard based on thick blood smear microscopy to RDT has enabled improved diagnosis of 
malaria in clinical settings since parasitemia is usually higher if a malaria infected person 
presents with clinical signs and symptoms. Clearly, HRP2 based RDT have limitations 
resulting in false positive (persistence of the PfHRP2 antigen after the parasite has already been 
eliminated) and false negative (lower limit of detection at 100 parasites/microliter) test results. 
Therefore, it is clear that RDTs do not measure all circulating P. falciparum infections, a 
limitation which is particularly important for larger scale malaria surveillance programs in 
regions with low malaria parasitaemia. 
In this thesis, we developed novel approaches and software tools to overcome these inherent 
limitations of RDTs. We collected used RDTs from malaria indicator surveys in Tanzania and 
Equatorial Guinea and developed a high-throughput novel approach to extract NA. These 
RDTs have been collected under field conditions and stored only at RT before being transferred 
into the laboratory for NA extraction. By running qPCR assays on the extracted NA, we have 
increased the sensitivity of the malaria detection and improved on the identification of likely 
false negative tests. Furthermore, we have been able to detect P. falciparum parasites carrying 
kelch13 mutations conferring artemisinin resistance and to expand the range of malaria species 
to P. malariae and P. ovale. 
The limiting hands on time, robustness and ease of conduct are prerequisites to use the ENAR 
approach also in malaria endemic countries in central reference laboratory facilities where 
qPCR machines are usually available. We plan to analyse RDTs collected during the MIS 2019 
on Bioko Island in our new laboratory facility in Baney resulting in the education of Equatorial 
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Guinean technical staff that can master molecular testing of malaria. The throughput of our NA 
extraction method from RDTs could be increased even further by automation using an 
extraction robot. One of the major limitations of using RDTs for NA extraction is the amount 
of blood (around 5 – microliter) that can be fixed on the nitrocellulose filters. 
In combination with regular malaria indicator surveys, our approach constitutes a convenient 
way of establishing a biobank that could be stored at room temperature for more than one year. 
This will not only allow retrospective studies of malaria in different populations of interest like 
pregnant women, but also the simultaneous monitoring of other blood borne pathogens present 
in the surveyed populations, including the helminth infections Loa loa and Mansonella 
perstans. These pathogens have been successfully detected using the ENAR approach in RDTs 
collected from Bioko Island (unpublished results). Apart from detection of NA from parasites, 
we will try as next steps if it is possible to detect NA from viruses such as Dengue virus that 
seems to be highly prevalent on the island of Bioko. Since human DNA is also fixed on the 
RDTs, our approach could be used to study the association of selected human genetic traits 
with pathogens without the need of collecting more blood samples under the umbrella of 
different study protocols.  
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